 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165046] number:  [STUDY_ID_REMOVED] 
 
Vibrant Ltd. 
Study Protocol 
 
  
Study number: V-270 
Protocol number: 270CLD  Protocol Date: Jan 24
th, 2019  
Rev. 01 
 A Prospective, Randomized, Multi-center, double-Blinded, Placebo-Controlled, 3-Arm Clinical Study 
to Assess the Efficacy and Safety of Vibrant 
Capsule, for the Treatment of Chronic Idiopathic Constipation 
 
Confidentiality statement: 
The following confidential information is the proper ty of Vibrant Ltd.  As long as the information 
contained in this protocol has not been published, it may only be used when permission has been 
obtained from Vibrant Ltd. in writing.  It is not permitted to make  reproductions of all or sections 
of this protocol.  Commercial use of the inform ation is only possible w ith the permission of the 
proprietor and is subject to a license fee.  
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165047] urer of the investiga tional device, legally 
represented by [CONTACT_207499]-Tsur, Chief Ex ecutive Officer, stat es the following: 
 
a. to assume responsibility related to the clinical investigation; 
b. that the treatments used to perform the c linical study are adequa te for the device under 
investigation; 
c. that the clinical study, as for the responsibility of the manu facturer, will be conducted in 
conformance with: 
 
The Federal Food, Drug, and Cosmetic Act, as am ended, and regulations promulgated thereunder 
(“the Act”) and the [LOCATION_002] Food and Dr ug Administration (“FDA” ) regulations governing 
the protection of human subjects  and regulations governing clinic al investigators, The World 
Medical Association Declaration of Helsinki, titl ed “Ethical Principles for Medical Research 
Involving Human Subjects”, ICH/GCP guidelines, Applicable relevant national legislation, 
HIPAA as defined in 45. C.F.R. section 164.501 or  relevant national equivalent and following 
revisions or other analogous inte rnationally recognized standards,  to be specified, and only after 
the approval, by [CONTACT_207500], of the investigational protocol, the informed 
consent and the documentation required  by [CONTACT_465063]; 
  
  
Print Name:  [INVESTIGATOR_7496]:   Date: 
 
            
      
 
     
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 3 of 99 
 
 
 
2. Investigator 	Agreement: 		
Prior to participation in this study, a written approval must be obtaine d from the In stitutional 
Review Board, and copy should be provided to th e Sponsor, Vibrant Ltd., or their authorized 
representatives, along with the Institutional Review Board appr oved Informed Consent Form.   
 
The Principal Investigator [INVESTIGATOR_38478]: 
 Conduct the study in accordance with the study protocol, the Investigator Agreement, 
Declaration of Helsinki, Good Clinical Practices, international harmon ized standards for 
clinical investigation of medical devices (Title  21 of the Code of Federal Regulations (21 
CFR), part 812 (Investigational Device Exempt ions), the laws and regulations of the 
countries where the study will take place, i ndemnity/insurance requirements and any other 
applicable regulations.   
 Agree to participate in an appropriate traini ng program as part of the study initiation. 
 Assure that informed consent is obtained fro m each subject prior to enrollment, using the 
Institutional Review Bo ard approved form.   
 Assure that the study is not commenced until  Institutional Review Board approval has 
been obtained. 
 Provide all required data and agree to sour ce document verification of study data with 
subject’s medical records.   
 Allow staff of the Sponsor and its authorized representatives,  as well as representatives 
from regulatory agencies, to review, inspect and copy any documents pertaining to this 
clinical investigation.  
 
The Principal Investigator (PI) ma y delegate one or more of the above functions to an associate 
or sub-investigator.  However, the PI [INVESTIGATOR_465056] r proper conduct of the 
study, including obtaining and docum enting subject informed consen t, compliance with the study 
protocol, and the collection of all required data. 
 
Principal Investigator [INVESTIGATOR_207486]: 
I the undersigned, have reviewed this protocol an d agree to conduct this st udy in adherence to the 
study protocol, GCP (Good Clinical  Practice) compliance, Ethical principles set forth in the 
declaration of Helsinki and authority regulations for the protection of human subjects 
participating in clinical trials. 
 
Print Name:  [INVESTIGATOR_7496]:   Date: 
 
-----------------    ----------------- ------  ---------------  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 4 of 99 
 
 
 
Table of Contents 
 
1. Sponsor Statement of compliance .................................................................................. 2  
2. Investigator Ag reement: ................................................................................................. [ADDRESS_1165048] of Abbr eviations ....................................................................................................... 7  
4. Protocol Sy nopsis ............................................................................................................ 9 
5. INTRODUCTI ON ............................................................................................................. 19  
6. BACKGROU ND ............................................................................................................... 19  
7. DEVICE NAME [CONTACT_207562] ............................................................................... 22  
7.1 Device Na me ................................................................................................................. 2 2 
7.2 Intended Use ................................................................................................................ 2 2 
8. DEVICE DESC RIPTIO N .................................................................................................... 22  
8.1 Capsule ....................................................................................................................... .. 23  
8.1.1  Vibrant Ac tive: .............................................................................................................. 23 
8.1.2  Vibrant Plac ebo: ........................................................................................................... 24  
8.1.3  Accessory: activati on base unit ..................................................................................... 25  
8.2 Capsules Acti vation  ....................................................................................................... 26  
9. RISKS & BENE FITS .......................................................................................................... [ADDRESS_1165049] & POPULATI ON ................................................................................. 43  
14.1  Inclusion Cr iteria ........................................................................................................... 43 
14.2  Exclusion Cr iteria .......................................................................................................... 4 4 
14.3  Duration of  Study  .......................................................................................................... 45  
15. STUDY TREA TMENT ...................................................................................................... 45  
15.1  Study De sign ................................................................................................................. 45 
15.2  Medical Hi story ............................................................................................................. 4 7 
15.3  Constipation Histor y ..................................................................................................... 47  
15.4  Physical Exam inatio n .................................................................................................... 47  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 5 of 99 
 
 
 
15.5  Assessment of pelvic floor dysfunc tion (defecator y disorder) ...................................... [ADDRESS_1165050] s .................................................................................................... 48  
15.7  Screening visit (day  -21 to -14) ..................................................................................... 48  
15.8  Run-in period (day - 21 or -14, to -1) ............................................................................. 49  
15.9  Baseline / randomization  visit (day  0) ........................................................................... 50  
15.10  4 weeks visit (d ay 28 ± 2) .............................................................................................. 51  
15.11  8 weeks visit / Terminat ion (day 56 ± 2) ....................................................................... [ADDRESS_1165051] udy protoc ol .................................................................................... 56  
15.18  Investigative Center Se lection Crit eria .......................................................................... 57  
16. ADVERSE EVENTS RECORDING ...................................................................................... 58  
16.1  Reporting Requi rements ............................................................................................... 58  
16.2  Definiti ons ................................................................................................................... . 58 
16.3  Anticipated Adve rse Even ts .......................................................................................... 60  
16.4  Adverse Event Reporting .............................................................................................. 61  
16.4.1  Intensity or Severity  ...................................................................................................... 61  
16.4.2  Relatedness................................................................................................................... 62 
16.4.3  Outcome .......................................................................................................................  62 
16.4.4  Treatment or Ac tion ta ken ............................................................................................ 62  
16.5  Expedited Reporting of Se rious Adverse Events ........................................................... 63  
16.6  Follow- Up of Unre solved Ev ents .................................................................................. 64  
17. STATISTICAL CONS IDERATIO NS ..................................................................................... 64  
17.1  Study Design and Objectiv es ......................................................................................... 64  
17.2  Study Endpo ints ............................................................................................................ 64  
17.2.1  Primary Efficacy  Endpoin t ............................................................................................. 64  
17.2.2  Secondary Efficacy  Endpoin ts ....................................................................................... 65  
17.2.3  Additional Effica cy Endpoin ts ....................................................................................... 65  
17.2.4  Safety Endp oints ........................................................................................................... 66  
17.3  Statistical Hy pothesis  .................................................................................................... 66  
17.4  Sample size ...................................................................................................................  66 
17.5  Interim Anal yses ........................................................................................................... 67  
17.5.1      Procedure ......................................................................................................... ....... 67  
17.5.2  Blindi ng ...................................................................................................................... ... 67  
17.5.3  Decision Rules ............................................................................................................... 67 
17.5.4  Controlling the Alpha level fo r the primary endpoint  ................................................... 69  
17.6  Randomizati on .............................................................................................................. 69  
17.7  Blindi ng ...................................................................................................................... ... 69  
17.8  Data Analysis  Sets  ......................................................................................................... 69  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 6 of 99 
 
 
 
17.8.1  Intent to Tr eat (ITT ) ...................................................................................................... 69  
17.8.2  Modified Intent to  Treat (m ITT) .................................................................................... 69  
17.8.3  Per-Protocol  (PP)  .......................................................................................................... 70  
17.8.4  Statistical Analysis of  Analysis Sets ............................................................................... 70  
17.9  Statistical Analysis ......................................................................................................... 70 
17.9.1  General Consid erations................................................................................................. 70  
17.9.2  Significance levels and hand ling of type I error ............................................................ 71  
[IP_ADDRESS]  Type I Er ror ............................................................................................................ 71  
[IP_ADDRESS]  Primary Endp oints ................................................................................................. 71  
[IP_ADDRESS]  Hierarchy Approach for Seconda ry Endpoints Analysis  ......................................... [ADDRESS_1165052] / STUDY DI SCONTINUAT ION ........................................................................... 80  
29. DEVICE ACCOUN TABILITY  ............................................................................................. 81  
30. APPENDIC ES .................................................................................................................. 8 2 
31. REFERENCES .................................................................................................................. 8 2 
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165053]	of	Abbreviations 	
 
% Percent 
AE 
ADE 
AGA 
AR Adverse Event 
Adverse Device Effect 
American Gastroenterological Association 
Authorized Representative 
BMI 
BUN 
CSBM Body Mass Index 
Blood Urea Nitrogen 
Complete Spontaneous Bowel Movement 
eCRF 
CI Electronic Case Report Form 
Confidence Interval 
CIC Chronic Idiopathic Constipation 
DSMB Data and Safety Monitoring Committee 
EC Ethics Committee 
ECG 
EDC 
FA 
FC Electrocardiogram 
Electronic Data Capture 
Full Analysis Set 
Functional Constipation 
GCP Good Clinical Practice 
FDA Food and Drug Administration 
IBS-C ICF Irritable Bowel Syndrom e with Constipation 
Informed Consent Form  
ICH International Conference on Harmoni zation of Technica l Requirements for 
Registration of Pharmaceuticals for Human Use 
IFU Instruction for Use 
IRB 
ISF Institutional Review Board 
Investigator Site Files 
ITT Intent To Treat 
Mg Milligram 
g Microgram 
Min 
MFR 
NCAs 
NSAIDs minute(s) 
Manufacturer 
National Competent Authorities 
Non-Steroidal Anti-Inflammatory Drugs 
mITT Modified Intent to Treat OTC 
PAC-QOL 
PEG Over The Counter 
Patient Assessment of Constipation Quality of Life questionnaire 
Polyethylene glycol 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165054]   
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 9 of 99 
 
 
 
4. Protocol 	Synopsis 	
Title A Prospective, Randomized, Multi-center, double-Blinded, Placebo-
Controlled, 3 Arm Clinical Study to Assess the Efficacy and Safety of 
Vibrant Capsule, for the Treatment of  Chronic Idiopath ic Constipation  
Indication The Vibrant Capsule is intended for the treatment of adult subjects with 
Chronic Idiopathic  Constipation. 
Objectives The objectives are to assess the efficacy and safety of Vibrant capsule 
administered 5 times per week  
Number of 
Subjects About 168 enrolled subjects including 10% drop-outs. 
 
Number of 
centers The study will be performed in about 30 centers   
 
 
Study 
Duration Study duration is 10 to 11 weeks 
- 2 to 3 weeks of run-in 
- 8 weeks of treatment  
Design The study is a prospective, randomiz ed, multicenter, ad aptive design, double 
blinded, placebo-controlled study, to ev aluate the efficacy and safety of 
Vibrant Capsule vs. placebo in relie ving constipation in subjects with 
Chronic Idiopathic  Constipation. 
 
Three arms will be assessed:  
- Vibrant Capsule mode A administered 5 times per week 
- Vibrant Capsule mode B administered 5 times per week 
- Placebo Capsule administe red 5 times per week 
The difference between the 2 operating modes is in the vibrating sequence 
durin g the capsule's operatin g time. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 10 of 99 
 
 
 
 
An interim analysis will be performed after about 90 evaluable subjects will 
complete 8 weeks of treatment. The following parameters will be assessed: primary endpoint, and main  safety parameters.  
  Depending on the results of  the interim analyis: 
 
 The study will be stopped, 
 The study will continue as planned 
 The sample size will be increased, 
 
In addition, the less pro mising treatment arm will be stopped (Drop-the-
losers design) and continue with the more promising treatment arm on 1:1 randomization of Vibran t Treatment VS placebo 
 
Method  Subjects  will come for 4 visits: Screening (v isit 1), baseline (visit 2), after 4 
treatment weeks from baseline (visit 3) and after 8 treatment weeks from 
baseline (Final visit , visit 4) . A total of 8 treatment weeks. 
 
Visit 1 - Screening: Subjects will be sc reened to the study at the screening 
visit, PAC-QOL questionnaire will be completed. Following this visit,  
subjects will have a run-in time for a pe riod of 2-[ADDRESS_1165055] eDiary each day  which includes 
questions on:  
 Daily BM, SBM, CSBM  
 Change of subject’s diet, if applicable (NOTE: the protocol will not 
ask/require the subjects to cha nge anything in his/her diet)  
 Change in sympotms as: brisol st ool consistency, straining, bloating, 
and the other questions in the eDiary    
 Medication 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 11 of 99 
 
 
 
 AE / change in general health condition  
 
Assessment of subject’s eligibility w ill be based on 14 consecutive days of 
this eDiary with an average of ≥1 SBM and ≤ 2.5 SBM per week . 
 
Visit 2 - Baseline: After the run-in period, the subjects will return and 
eligibility will be re-asse ssed. Subjects will be randomized to either Vibrant 
mode A or B  or Vibrant placebo for a treatment pe riod of [ADDRESS_1165056] 2 weeks of treatment will be  considered as a subjects’ training 
period. 
 
Visit 3 – after [ADDRESS_1165057]'s treatment efficacy and safety. Capsules  for additional 4 
weeks of treatment will be dispensed to the subjects . 
  
Visit 4 - Final visit –after another [ADDRESS_1165058]'s treatme nt efficacy and safety. The base units 
and remaining capsules will be collected.   
PAC-QOL, Ease of use and TSQM questionnaires will be completed. 
During the entire study period, data reporti ng will be done on an electronic 
Case Report Form (eCRF) and an eDiary. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165059]’s compliance will be 
monitored throughout the 8 weeks of the study. 
Subjects will be authorized to use rescue medication after 3 consecutive 
days without a bowel movement. 
 
Endpoints Primary endpoints: 
 
Efficacy Endpoints: 
The two primary efficacy endpoints are the CSBM1 success rate, defined as 
an increase from the run-in period of at least one weekly Complete 
Spontaneous Bowel Movement (CSBM) dur ing at least [ADDRESS_1165060] two weekly Comp lete Spontaneous Bowel Movement 
(CSBM) during at least 6 of the 8 weeks of treatment. 
 
The study will be deemed successful if  either the CSBM1 or the CSBM2 
success rate is statistically significantly higher in the active arm that was 
continued after the interim analysis, than in the placebo arm. 
 NOTE:  
• A spontaneous bowel movement (SBM) is defined as a bowel 
movement that occurs at least 48h after laxative/res cue intake and 
without digital maneuver. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 13 of 99 
 
 
 
• A complete spontaneous bowel move ment (CSBM) is defined as a 
spontaneous bowel movement associat ed with a feeling of complete 
evacuation by [CONTACT_423] . 
  
 
 
 
Safety Endpoints: 
Safety endpoints include all adverse events related and unrelated to the 
study treatment 
Secondary Efficacy Endpoints: 
 
Secondary efficacy endpoints include:  
• Change from baseline in average straining. 
• Change from baseline in average st ool consistency, using the Bristol 
Stool Scale 
• Change from baseline in  average bloating. 
 
Additional Secondary Efficacy Endpoints:  
Additional secondary efficacy endpoints include: 
• CSBM1 success rate when using the data from the two active arms 
together. 
• CSBM2 success rate when using the data from the two active arms 
together. 
• SBM success rate, defined as an increase from baseline period of at 
least one weekly Spontaneous Bo wel Movement (SBM) during at 
least 6 of the  8 weeks of treatment. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 14 of 99 
 
 
 
• Incidence of Rescue Medication use during the treatment period 
• Change from baseline in weekly  number of Spontaneous Bowel 
Movement (SBM). 
• Change from baseline in weekly number of Complete Spontaneous 
Bowel Movement (CSBM). 
• Rate of SBM ≤ [ADDRESS_1165061] dose 
• Change from baseline in average abdominal gas. 
• Change from baseline in average abdominal pain. 
• Change from baseline in abdominal discomfort. 
• Time to occurrence of spontane ous bowel movement after first 
capsule activation. 
• Treatment satisfaction score using the TSQM (Treatment 
Satisfaction Questionnaire for Medication) 
• Change from baseline in quality of  life using the PA C-QOL (Patient 
Assessment of Constipation Qual ity of Life) questionnaire.  
 
Subject 
Population Subjects with Chronic Idiopathic Constipation refractory to existing 
treatments.  
Inclusion criteria 1. Subjects aged 22 years and older 
2. Subjects with Chronic Idiopathic Constipation (CIC) according to 
Rome III criteria and who have not experienced relief of their 
symptoms from available therapi[INVESTIGATOR_014] (osmotic and stimulant laxatives 
used for at least one mo nth at recommended dose) 
3. Subjects with an average of ≤2.5 Spontaneous Bowel Movements 
(SBM) per week and ≥1 SBM per week  
4. Normal colonoscopy performed wi thin 5 years prior to study 
participation, unless th e subjects are <50 years old and without alarm 
signs and/or symptoms 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165062] signed the Inform ed Consent Form (ICF) 
6. Female subjects must have a nega tive blood pregnancy test during 
screening, confirmed by a negati ve urine pregnancy test during 
baseline and must not be l actating prior to receiving study 
medication. For females of child-be aring potential, a hormonal (i.e., 
oral, implantable, or injectable ) and single-barr ier method, or a 
double-barrier method of birth contro l must be used throughout the 
study. All other female subjects mu st have the reason for their 
inability to bear children documen ted in the medical record [i.e., 
tubal ligation, hysterectomy, or post-menopausal (defined as a 
minimum of one year since the la st menstrual period)]; in these 
circumstances, a pregnancy te st will not be necessary.  
 
Exclusion criteria 1. History of complicated/obstr uctive diverticular disease 
2. History of intestinal or colonic obstruction, or suspected intestinal 
obstruction. 
3. History of significant ga strointestinal disorder , including any form of 
inflammatory bowel disease or ga strointestinal malignancy (celiac 
disease is accepted if th e subject has been treated  and is in remission) 
4. History of gastroparesis 
5. Use of any of the following medications:  
o Medications that may affect intestinal motility, prokinetics, 
anti-Parkinsonian medications , opi[INVESTIGATOR_858], opi[INVESTIGATOR_2438], calcium-
channel blockers, alumin um/magnesium hydroxide 
o With the exception of antidepressants, thyroid or hormonal 
replacement therapy, when the subject has been on a stable 
dose for at least 3 months  prior to enrollment. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 16 of 99 
 
 
 
6. Clinical evidence of significant re spi[INVESTIGATOR_696], cardiovascular, renal, 
hepatic, biliary, endocrine, psychi atric or neurologic disease. 
7. Presence of cardiac pacemaker or gastric electrical stimulator. 
8. History of, or current ea ting disorders, such as  anorexia, bulimia, or 
compulsory overeating. 
9. Diagnosis of mega-rectum or  colon, congenital anorectal 
malformation, clinically significant re ctocele, history of intestinal 
resection (with an exception for appendectomy, cholecystectomy and 
inguinal hernia repair), history of bariatric surgery or evidence of any 
structural abnormality of the gastrointestinal tract that might affect 
transit 
10. History of Zenker’s diverticulum , dysphagia, Barrett's esophagus, 
esophageal stricture or achalasia 
11. Chronic use of non-steroidal anti -inflammatory drugs (NSAIDs): 
chronic use is defined as taking full dose NSAIDs more than three 
times a week for at least six m onths. Subjects on cardiac doses of 
aspi[INVESTIGATOR_152360]  
12. Subjects with pelvic floor dysfunc tion/defecatory disorder, based on 
subject history 
13. Participation in another clinical  study within one month prior to 
screening. 
14. Women who are pregna nt or lactating 
15. Use of any medication for constipat ion relief during the study, except 
as rescue medication, as  indicated by [CONTACT_207502] 
16. Inability to use an electronic daily Diary (on a computer, phone 
application, tablet or other el ectronic device) to report bowel 
movements, symptoms and medication usage 
17. Subject participated in a previous Vibrant study 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165063]'s 
ability to comp lete the study 
Statistical 
analysis  Study Hypotheses: 
In this study, we will test  the following hypotheses: 
 H0 : P a1-Ps1=0 
 H1: Pa1-Ps1≠0 
Where P a1 is the CSBM1 success rate in the selected active arm, 
and P s1, the CSBM1 success rate  in the placebo arm. 
AND: 
 H0 : P a2-Ps2=0 
 H1: Pa2-Ps2≠0 
Where P a2 is the CSBM2 success rate in the selected active 
arm, and P s2, the CSBM2 success rate in the placebo arm.  
 
Sample size: 
A sample size is calculate d to test the null hypothesi s. Calculations (using 
SAS® proc power) show that a sample size of 150 subjects (60 in the 2 
study arms that will be continued ti ll the end of the study, and 30 for the 
study arm that will be dropped at the in terim analysis), would provide 80% 
power at  a study wise 5% level of significance (two-sided ), i.e. 2.5% for 
each one of the primary endpoints to detect a difference of 25% in the 
success rate, assumin g a success rate of 15% in the placebo arm.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165064] 168 subjects (67 in the 2 study 
arms that will be continued till the end of the study, a nd 34 for the study 
arm that will be dropped at the interi m analysis) to account for a potential 
10% of drop-out rate.  Main Efficacy Analysis: 
 
The subject’s CSBM1 success status (i.e. if the subjects achieve an increase 
from baseline of at least [ADDRESS_1165065] 6 out of the 8 
treatment weeks will be presented in tabular form by [CONTACT_30157], along with 
95% Wilson score Confidence Intervals (CI) and will be compared between 
the study arms with a Cochran-Mantel-H aenszel test controlling for center. 
 
The CSBM2 success rate will be anal yzed in the same manner.  
	
 	
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 19 of 99 
 
 
 
5. INTRODUCTION 	
 
This document is a clinical research prot ocol and the described study wi ll be conducted in complianc e with the protocol, standa rds of 
Good Clinical Practices and asso ciated regulations, and all app licable research  requirements. 
 
6. BACKGROUND 	
 
Chronic constipation is a common gastrointes tinal disorder in the general population. It  is estimated that chronic constipation  affects 
between 2 and 27% of the population. A majori ty of chronic constipation sufferers are women, who repr esent three-fourths of tho se 
affected1. 
Constipation may be primary (Chronic Idi opathic Constipation (CIC), Irritable Bowe l Syndrome with Cons tipation (IBS-C)) or 
secondary to other factors (such as drugs lik e opi[INVESTIGATOR_2438], colorectal cancer, diabetes, Pa rkinson’s disease or spi[INVESTIGATOR_1828]) . It is 
estimated that 100 million a dults in the [LOCATION_002] (US) have chronic pain2.  
There is no widely accepted definition of  chronic constipation. Although physicians often define constipation based on stool 
frequency, subjects experience constipation as a multi-symptom disorder that includes in frequent bowel movements, hard or lumpy  
stools, straining, bloating, a feeling of incomplete evacuation after a bowel movement and abdominal discomfort3. The Rome 
Foundation has created symptom-based diagnosti c criteria for chronic cons tipation. To meet the defini tion of chronic constipati on, the 
criteria must be fulfilled for the prior [ADDRESS_1165066] co sts of IBS to range from approximately $ 1,600 
to $7,[ADDRESS_1165067] costs of CIC range fro m approximately $1,900 to $7,[ADDRESS_1165068]- year6. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165069] 
symptoms and preferences. 
Constipation Management  
The American Gastroenterological Associa tion (AGA) has established a treatment algor ithm for constipation th at provides multipl e 
therapeutic steps depending on severity of symptoms.  See http://www.gastrojournal.or g/article/S0016-5085(12)[ZIP_CODE]-4/pdf . The first 
step in the treatment of constipa tion focuses on lifestyle modification  with three main parameters: ade quate fluid intake, a high fiber 
diet and regular physical activity. 
Fiber absorbs water, increases stool bulk, a nd in doing so stimulates the bowel to decr ease stool transit time and ease evacuat ion.  
Medicinal and dietary fiber supplements, such as psyllium, can be  added to the high fiber diet or used as primary therapy. 
If lifestyle modification does not produce sa tisfactory results, subjects have access to a number of FDA-approved products (Foo d and 
Drug Administration), available both over th e counter (OTC) and by [CONTACT_50246]. Stool softeners (docusate sodium, docusate cal cium) 
act by [CONTACT_207503], ma king the stool softer, which makes it easie r and 
less painful to pass. However, th ere is currently limited data on the efficacy of  stool softeners in subj ects with constipation1.  
Osmotic laxatives are also available, incl uding polyethylene glycol (P EG), lactulose, magnesium hydroxide, magnesium citrate, 
magnesium sulfate, and sodium phosphate. PEG and lactulose have been shown to improve stool frequency and stool consistency1,6,7.   
Osmotic laxatives contain poorly absorbed i ons or molecules that retain  water in the intestinal lu men. Although effective, they  can 
cause bloating and crampi[INVESTIGATOR_007].  In addition, due to their mechanism of  action, they should be used w ith caution in older adults a nd in 
subjects with renal impairment because of the ri sk of dehydration and el ectrolyte disturbances. 
Stimulant laxatives include senna, bisacodyl or sodium pi[INVESTIGATOR_207489]. They induce flui d and electrolyte secretion by [CONTACT_838662] o r 
induce peristalsis in the colon, th ereby [CONTACT_133239] a bowel movement.  
Recent advances in research have resulted in new classes of medication for the trea tment of constipation, available on prescrip tion. 
For example, linaclotide is an agonist of  guanylate cyclase-C receptors, and increase s chloride, bicarbonate  and fluid secretio n into the 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 21 of 99 
 
 
 
intestinal lumen, lubricating th e stool and accelerating gastrointestinal transit. Linaclo tide was FDA-approved in 2012 for CIC  and 
IBS-C. Adverse events include diarrhea, which leads to disc ontinuation of the medication in approximately 5% of subjects8.  In total, 
8% of subjects in linaclotide clinical trials discontinued due to adverse events, and 27% had their dose reduced or suspended 
secondary to adverse reactions, the major ity of which were diarrhea or other gastrointestinal  adverse reactions.  See 
http://www.accessdata.fda.gov/drug satfda_docs/label/ 2014/202811s004lbl.pdf  
 
Lubiprostone is approved for use in women with IBS-C and in men and wo men with CIC, as well as opi [INVESTIGATOR_2480]-induced constipation in 
subjects with non-cancer pain. It is a sele ctive chloride channel activ ator, increasing ion and flui d secretion. The main adver se events 
associated with lubiprostone are mild to moderate nausea and diarrhea2,9.  Approximately 29% of subject s who received lubiprostone 
24 mcg twice daily in clinical trials experienced nausea; 4% of  subjects had severe nausea while  9% of subjects discontinued 
treatment due to nausea. Approximately 12% of subjects who received lubi prostone 24 mcg twice daily experienced diarrhea; 2% ha d 
severe diarrhea while 2% discontinued treatment due to diarrhea.  In addition, it has b een reported to cause dyspnea, which was  
reported in 2.5% of the treated  chronic idiopathic c onstipation population and 0.4% in the treated IBS-C population. Although n ot 
classified as serious adverse events, some subjects discontinued treatment because of this event. These events have usually bee n 
described as a sensation of chest tightness a nd difficulty taking in a breath, and gene rally have an acute onset within 30-[ADDRESS_1165070] dose. They generally  resolve within a few hours after taking the dose, but re currence has been frequentl y reported 
with subsequent doses.  See http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2008/021908s005lbl.pdf .   
In subjects with severe chronic constipa tion, surgery may be considered ; however, it is generally limi ted to use in the most se vere 
cases after medical management has failed to  provide adequate relief.  In subjects wi th severe incapacitating slow transit cons tipation, 
colectomy with ileorectal anastomosis can  improve constipation and related symptoms10,11. 
In summary, while there are a variety of treatments available for constipation, ther e is currently no satisfactory treatment fo r many 
constipated subjects:  a US study showed that 47% of constipated subjects are no t completely satisfied w ith their current const ipation 
treatment3, while a European study showed that only 27% of European subjects are satis fied with current treatment options5. 
Furthermore, many subjects become refractor y to one or more OTC laxatives with chro nic use, which may cause frustration for bot h 
the clinician and the subject, and ultimately leads many subjects  to abandon therapy and remain  dissatisfied with their conditi on2. 
Nearly 90% of subjects expre ss interest in new therapi[INVESTIGATOR_014]12.   
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165071] not experienced relief of their symptoms from available therapi[INVESTIGATOR_014] (osmotic  and 
stimulant laxatives used for at least 1 m onth at recommended dosage). The capsule achi eves its purpose by [CONTACT_688981]  a 
bowel movement in the large intestine. 
 
  
8. DEVICE	DESCRIPTION 	
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165072] in the larg e intestine, thus aiding in relieving cons tipated 
subjects. Constipation relief is achieved by [CONTACT_182597]’s vibra tions impi[INVESTIGATOR_838654],  consequently indu cing 
peristaltic activity which promotes transit and facilitates defecation. 
 
The Vibrant Capsule has se veral important features: 
 Small Dimensions. 
 Easy to swallow (smooth shell). 
 Mode of Operations - defines the vibrat ion start time, vibration dur ation, sequence, and force and rest time between the 
vibration cycles. In this study 2 different Modes of Operations will be evaluated. 
The capsule is activated by [CONTACT_838663].  
 
8.1 Capsule 
8.1.1 Vibrant Active:  
The Vibrant non-biodegradable capsule is comp rised of a flat motor, electronic card a nd batteries, all encapsulated in a 2-pi[INVESTIGATOR_125382] e shell 
(please refer to Figure 1 below). The capsule  is activated by [CONTACT_838664] s the Activation Code using  the 
activation base unit, prior to swallowing the capsule.    
 
 
 
 
 
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 24 of 99 
 
 
 
 
  
The capsule dimensions are: 
 Length : 24.2 ± 0.1 mm 
 Diameter : 11.3± 0.1 mm 
 
The capsule shell is made of a well-know n biocompatible material: PC MAKROLON 2458. 
Shell is hard & non-biodegradable.  
Before starting the vibrating action and to ensure the capsule has arrived at the larg e intestine, the company has integrated a  tightly 
controlled vibrating algorithm, i.e. multi vibration sessions.  
 
 
 
The capsules are packaged in a blister (cf. Fig. 2 below).  
 
 
 
Figure 2.  The blister  
 
8.1.2 Vibrant Placebo:  
The placebo capsule is a white colored, softge l biodegradable capsule fille d with soybean oil, beeswax and Calcium Carbonate, w hich 
is visually similar to th e Vibrant active capsule.  
  Figure 1. The capsule and components  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 25 of 99 
 
 
 
8.1.3  Accessory: activation base unit 
 
A user friendly activation base was de veloped by [CONTACT_56637] y for subject use 
(please refer to Fig 3 below). The activation base (or base unit) is mean t to be used at home by s ubjects. The base unit is eas y to use 
and requires a simple training before taking it home. Subj ects will activate the capsule themselves at home.  
 
 
 
The activation base is composed of: 
  An electronic circuit board  
  Electromagnetic antenna bedding the capsule.  
The Activation base is provided in a protectiv e package containing th e following (see Fig.3): 
- Base Unit 
- USB cable  
- AC/DC USB adapter  
- Instructions for use  
 
  
 
 
1. Base Unit 
2. USB cable  
3. AC/DC USB adapter  
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 26 of 99 
 
 
 
 
  
 
 
1. Base Unit Cover 
2. The "Ready" Green Light Indicator 
3. The Designated Groove for Capsule 
4. The "X" Red Light Indicator 
5. The "ON" Green Light Indicator 
 
 
 
 
Figure 3. Activation base: desc ription of components and image 
 
 
 
 
Setting up the base unit 
First, the user connects the base unit to an electricity outlet,  with the USB cable and AC/DC ad apter. The green “ON” light on the base 
unit turns on indicating, th at the base unit is conne cted to electricity  
 
  
8.2 Capsules Activation 
1. The capsule will be placed in the designated groove in the center 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165073] after it stops to vibrate in the groove  
3. Capsule will reach the large intestine and start predef ined vibrating program, induc ing peristaltic activity.  
4. Capsule will be extracted from the body during normal bowel movement. 
 
Additional details can be found within the Investigator's Broc hure (Document # 114CLD,) the Inst ruction For Use (IFU) for the 
vibrating capsule (Document # 117LAB) and User Manual (Document # 113CLD). 
 
9. RISKS	&	BENEFITS 	
 
The Vibrant Capsule is designed according to  international standards for medical devi ces. Compliance with these standards ensur es 
that the device can be used safely in human beings.  
Biocompatible materials are used for the vi brating capsule components. The use of biocompatible ma terials should protect the su bject 
of any hazardous from po ssible adverse events.  
 
The device classification according to ISO10993-1 and FDA’s guidance Use of International Standard ISO-[ZIP_CODE]-1:2009, 
"Biological Evaluation of Medical Devices  Part 1: Evaluation and Testing" :  Dr aft Guidance for Industry and Food and Drug 
Administration Staff (“FDA Biocompatibility Guidance”) is as follows:  
Category:  Surface device. 
Contact [CONTACT_24109]: perman ent contact (>30 days) 
Contact:  [CONTACT_207508]. 
 
According to this classification, the follo wing tests were performed, all of which had passing results: Cytotoxicity Study Usin g the 
ISO Elution Method, Bacterial Reverse Mutati on Study, ISO Intracutaneous Study in Rabbits , ISO Systemic Toxicity Study in Mice,  
ISO Guinea Pig Maximization Sensitization Test, Mouse Peri pheral Blood Micronucleus Study, Genotoxicity: Mouse Lymphoma 
Assay, ISO [ZIP_CODE]-18 - Chemical Characterization 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 28 of 99 
 
 
 
A biological risk assessment  of the Vibrant Capsule has also been performed by [CONTACT_207509] [ZIP_CODE]-1:[ADDRESS_1165074] results on the device to support and demonstrate th e overall 
biological safety of the Vibrant Caps ule. This assessment focu ses on the requirements of ISO [ZIP_CODE]-1:2009, EN ISO [ZIP_CODE]:2012, 
FDA General Program Memorandum #G95-1 a nd the 2013 Draft Biocompatibility Guidan ce, and the European Union Medical 
Device Directive 93/42/EEC. 
 
The company also evaluated the mechanical, structural integrity, electrical safety, shelf life and other characteristics of the  Vibrant 
Capsule when subjected to clinical use conditions.  
 
Testing performed incl uded the following:  
a. Visual inspection 
b. Dimensional verification of the capsule 
c. Mode of Operation test 
d. pH Resistance test 
e. Mechanical integrity test  
f. Electrical safety and EMC  
g. Environmental and tr ansportation test. 
 
   
9.[ADDRESS_1165075] in the large intestine, thus aiding in r elieving 
constipated subjects.  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165076], there will be no unwanted outputs of energy or substance. This has 
been evaluated and confirmed in prec linical testing (please refer to th e study investiga tional brochure). 
 
The capsule coating (a biocompati ble and widely used shell) prot ects the subject from any potential hazards that might be assoc iated 
with its contents. The energy of the batteries is harmless and cannot leak while the capsule remains inta ct (break force was te sted up to 
60 Kgf/cm²). The capsule was tested for Safety and EMC [ZIP_CODE] tria ls. No ionizing radiation is emitted and no thermal energy 
generated. 
 
Device manufacturing and assembly is done in an ISO [ZIP_CODE]:2003 facility. 
 
 
Adverse events 
Potential adverse events associated with the use of this device  may include abdominal pain, bloo d in stool and diarrhea. In rar e cases 
obstruction may occur  
 
Warnings: 
 The Vibrant Capsule has not been evaluated for safety and compatibility in the MR (magnetic resona nce) environment. It has 
not been tested for heating, migration, or image artifact in th e MR (magnetic resonance) envi ronment. The safety of the 
Vibrant Capsule in the MR (magnetic reso nance) environment is unknown. Scanning a s ubject who has this device may result 
in patient injury  
 before using this product  pleas e read the clinical applications  and risks associated listed in  the Instruction for Use (IFU)  
 If you have reasonable doubt concerning th e integrity of a Vibrant capsule, it should not be used and discarded 
 A Vibrant capsule should not be in gested after its expi[INVESTIGATOR_320] 
 Avoid biting the Vibrant capsule prior to swallowing 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 30 of 99 
 
 
 
 After ingesting a Vibrant capsule and until it is excreted, you should not be near any source of powerful electromagnetic field s 
such as one created near an MRI device 
 The capsule should be kept away  from implants such as pacemake rs, defibrillators, ne rve stimulators, and other devices that 
could be affected by [CONTACT_465069] a DC (direct current) magnetic field 
 If after ingesting a Vibrant capsule you experience any abnor mal abdominal pain, nausea or vomiting, you should contact a 
physician immediately  
 Vibrant capsules must be stored in a safe place,  out of the reach of children and/or infants  
 If a child has accidentally swallowed an unused Vibrant caps ule, he/she should be brought  immediately to a hospi[INVESTIGATOR_307]  
 Undergoing an MRI while the capsule is insi de your body may result in serious damage  to your intestinal tract or abdominal 
cavity. If you require an MRI instruct your  physician to verify capsule expulsion vi a abdominal X-ray before undergoing an 
MRI examination  
 The safety of this device has not been es tablished in pregnancy and/or lactation  
 The safety of this device in subjec ts with significant gastrointestin al diverticular disease is unknown  
 The safety of this device has not been established in adolescents  
 
 
Safety in Animal and Human Clinical Investigations  
No safety concern was raised during an imal and human clinical investigations. 
 
The animal studies and human inve stigation studies demonstrated safety of the capsule to suppor t subsequent studies in the 
target population. All capsules were extrac ted safely with no related serious advers e events and all clin ical and laboratory 
results were within normal values. For more detail s see section 11: Human Clinical Investigations. 
 
9.2 Benefits 
 
Human Clinical Investigations 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 31 of 99 
 
 
 
 
Phase 1, 2a and 3 studies showed clinical benefits with the Vibrant Capsule: the cap sule increased the num ber of weekly SBM / 
CSBM among subjects with constipation and improved constipation symptoms , such as straining, bloati ng and stool consistency. Fo r 
more details see section 11: Human Clinical Investigations. 
 
 
10. ANIMAL	INVESTIGATIONS 	
 
Two animal studies were conducte d using the Vibrant Capsule: 
The initial study was approved by [CONTACT_838665] (approval no. IL-089-09-2008), and performed at the 
Technion – Israel Institute of Technology. Th e study was overseen by [CONTACT_838666]. S tudy 
objectives were to evaluate th e safety and physiological effect  of the vibrating capsule in 3 dogs. On study initiation the dog s were 
given sham capsules to evaluate defecation time, clear passage of the capsule and safe ty. After approximately 1 week each anima l 
swallowed a vibrating capsule in different  intervals starting from 3 days to two week intervals duri ng a 6-month period. 
 
Final analysis showed that the capsules we re safe for use – they were  not damaged even when bitten by [CONTACT_207514]. There was no 
evidence of any discomfort or adverse eff ects on the dog’s health. Eviden ce of effectiveness of the capsule was indicated by [CONTACT_838667] , without creating artificial co nstipation conditions in the dog 's 
gastrointestinal tract.  
 
The second study was conducted at the Rambam Hospi[INVESTIGATOR_207492], Israel.  The study wa s approved by [CONTACT_688985] (approval no. IL-130-11-2009).  
Study objectives were to evaluate the safety  and physiological effect of  vibrating capsule in 2 dog s. On study initiation the d ogs were 
given sham capsules to evaluate defection time, clear passage of the capsule and safe ty. After approximately 2 days each animal  
ingested a vibrating capsule every second day for two weeks' tim e and was followed for an additio nal month. Capsule delay time was 
adjusted for the animal model (8 hours for a smaller dog and 16 hours fo r a bigger dog). Clinical obs ervations were recorded by  [CONTACT_207517], pa in, vomiting or irregular beha vior. In addition X-ray was used to verify capsule lo cation and 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 32 of 99 
 
 
 
vibrating movement. The time of  defecation and stool consiste ncy were recorded. The capsule s were retrieve d from the dog 
stools. Capsule integrity was conf irmed; capsules were whole with no defects in seal, no ruptures, no shell cracks or any other  
damage.   
 
In all the animals the cap sule were passed by [CONTACT_838668] t any adverse effects to the dog a nd/or any damage to the capsules . There 
was no evidence that the capsule's colon tran sit or its vibration caused any adverse ef fect to the dog's physical health and be havior.  
Evidence of effectiveness of the capsule was indicated by [CONTACT_838669]. 
Moreover, one dog suffered from cons tipation for 4 days (not indu ced by [CONTACT_1758]), which was re lieved by [CONTACT_465077] .  
 
11. HUMAN CLINICAL INVESTIGATIONS 
 
Vibrant Ltd. has completed  five human clinical investigations.  
 
Total Exposure – Human Clinical Investigations 
The human clinical investigations  performed by [CONTACT_207521] a total of 449 part icipants, healthy or constipated, to either t he 
Vibrant Capsule or the Sham Capsule. 
In total, 259 subjects received the Vibrant Capsule.   
 
The remaining 190 subjects who partic ipated in clinical investigati ons received the Sham Capsule. 
 
Phase 1 clinical investig ation – healthy volunteers 
 
An initial clinical study was appr oved and initiated in 2 sites in  Israel (Tel-Aviv Sourasky Medi cal Center and The Holy Family  
Hospi[INVESTIGATOR_307], Nazareth), from March 8 to 24th, 2011. The study was initially approved for use in 6 healthy volunteers in order to evaluate 
the safety of the Vibrant Capsule in a pr ospective, open-label,  single group study. 
Six consecutive healthy volunteers (3 men a nd 3 women) ages 21 to 41 years, all fulf illing the exclusion/ex clusion criteria, we re 
enrolled in the study. During the Baseline st udy visit, subjects were evaluated for el igibility and went through physical exami nation, 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 33 of 99 
 
 
 
vital sign measurements, ECG meas urements and blood tests, which were all within  the normal values. Elig ible subjects were aske d to 
take 1 vibrating capsule by [CONTACT_838670] l.  Subjects were followed for 7 days on  their normal bowel movements and excreti on of 
the capsule.  One week following the baseline  visit, subjects returned for a visit and repeated the physical  examination, vital  sign 
measurements, ECG measurem ents and blood tests.  
All capsules were evacuated from  the body, along with stoo l, safely with no adverse events. Average time for capsule excretion was 
2.2 days ([ADDRESS_1165077]). All clinical and laboratory results were withi n normal 
values.  Thus, this preliminary study dem onstrated safety of the capsule to support subsequent studies in the target population . 
 
Phase 2a clinical investigation   
V-111: "A Prospective, open-label, safety ev aluation of the Vibrating capsule in ai ding reliving constipated individuals" 
The study was conducted in the Departments of Gastroenterology and Hepatology at the Te l-Aviv Sourasky Medica l Center and at Th e 
Nazareth Holy Family Hospi[INVESTIGATOR_307], beginning in July 2011.  
Study design: Prospective, Open Label, Si ngle Group Assignment, Safety pi[INVESTIGATOR_16116].  
Objective: safety  
Study population: 26 Subjects with Ch ronic Constipation or Irritable Bo wel Syndrome With Constipation 
Endpoints: The primary endpoint was safety, assessed descriptively by [CONTACT_838671] (AEs ), clinical laboratory tes t 
results, vital sign measuremen ts, and ECG measurements.  
The secondary endpoint was efficacy , determined as an increase of more than one  spontaneous bowel movement (SBM)/week during 
the 7.5 weeks of treatment compared to the 2-week run-in period.  The number of spontaneous bowel movements was calculated as a  
weekly average. 
Methods: 2 capsules/ week for [ADDRESS_1165078] , before the next capsule was administrated.  
Results: Safety - [ADDRESS_1165079] s (36.4% of the subjects), none  of them was serious. 8 AEs  were 
possibly related to study device for 5 subjects (22.7% of the subjects) 
Efficacy - Mean increase of SBM =1.78, Std=1.09, p<0.001 
Conclusion: The Vibrant capsu le found to be safe.  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 34 of 99 
 
 
 
The next study was conducted to eval uate safety and efficacy (V-179) 
  
 
Comparative clinical investigation   
V-179: "A multinational, mu lticenter, prospectiv e double-blind, sham controlled, randomized st udy to assess the performance, efficacy 
and safety of Vibrating Caps ule medical device in aiding re lieving Constipated Individuals " 
 
The study was conducted in 16 sites (10 in the [LOCATION_003] and 6 in Israel) from Aug 2014 until Jan 2016. 
Study design: The study was a multinational, multicenter, prosp ective, randomized, double-blind, sham controlled trial. Identic al 
capsules were used in the sham arm, eli minating only the activation of the capsule in  the large intestine, for the sham group.  
Study objectives: The purpose of the investigation was to evaluate the efficacy and safety of the Vibrant Capsule compared to a  sham 
non-vibrating capsule on spontaneous bowel movements 
Study population: 154 (77 in each group)  Subjects with Chronic Idiopath ic Constipation according to Ro me III criteria who failed 
currently available therapy (osmotic and stimulant laxatives wh ich was used for at least one month at recommended dose).  
 
Endpoints: the primary endpoints were safety and efficacy.  
Safety: related AE's/SAE's 
Efficacy: an increase of at least [ADDRESS_1165080] 6 (of 8) weeks during the treatment period and 
improvement of at least 1 point  in PAC-QOL from baseline.  
 
The secondary endpoints were:  
1. Change from baseline in weekly SBM 
2. Time from fist Vibrant pi[INVESTIGATOR_69653] (either active or sham) to first SBM 
3. Number of rescue therapy uses  during the treatment period 
4. Change from baseline in PAQ-QOL score 
5. Change from baseline in stool consistency as  classified with the Bristol stool chart 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 35 of 99 
 
 
 
 
Methods: 2 capsules/ week for 8 weeks of treatment 
Results: A total of 252 Adverse Events (AE’s) were reported in the active arm and 183 in the sham arm. 2 AE’s  were considered s erious: 
[ADDRESS_1165081] ome considered not related 
 
A summary of adverse events severity is provided below.  
 
 
 
  
  Vibrant Group Sham Group 
Number 
of reports Number of 
subjects IncidenceŦ Number of 
reports Number of 
subjects IncidenceŦ 
Any Adverse Event 252 51 62.20% 183 44 54.32% 
Mild 203 42 51.22% 136 34 41.98% 
Moderate 47 21 25.61% 44 18 22.22% 
Severe 1 1 1.22% 1 1 1.23% 
Adverse Event Leading 
to Discontinuation 0 0 0% 0 0 0% 
Ŧ The incidence is defined as the percent of subject’s reporting a specific AE at least once, out of the total number of subject s in that group.  
 
The primary efficacy endpoints results are:  
1. SBM: 45.45% vs. 46.75% in Vibrant a nd Sham respectively (p= 0.8552).  
2. In a sub-group analysis  50% of the population (N=77) (Pts  who have avg of 1-2.5 SBM at baseline): SBM: 59.5% vs. 47.5% in 
Vibrant and Sham respectively (p=0.2933). CSBM: 35.1% vs . 15.0% in Vibrant and Sham  respectively (p=0.0406) 
3. Improvement of QOL from baseline:  26.1% vs. 32.0% in Vibrant and Sham respectively (p= 0.4409) 
 
The secondary endpoints results are: 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 36 of 99 
 
 
 
1. Change from baseline in stool consistency: Average change from ba seline in Bristol score: 0.9 vs . 0.6 Vibrant and Sham respecti vely 
(p=0.1303)  Sub-group analysis - Average change from baseline in Bristo l score: 1.1 vs 0.6 Vibrant and Sham respectively (p=0.0428) 
2. Change from baseline in bloating: Average ch ange from baseline in Bristol score: -1.8 vs. -0.8 Vibrant and Sham respectively 
(p=0.0 345) Sub-group analysis - Average change from baseline in bl oating: -2.0 vs -0.5 Vibrant and Sham respectively (p=0.0 043) 
3. Change from baseline in straining: Averag e change from baseline in Bristol score: -2.3 vs. -1.5 Vibrant and Sham respectively 
(p=0.0 824) Sub-group analysis - Average change from baseline in stra ining: -2.8 vs -1.3 Vibrant a nd Sham respectively (p=0.0 082) 
4. Responders from both arms used significan tly less rescue medication than patients w ho were not responders (p<0.0001 for Vibrant  
group, p=0.0002 for Sham): in the Vibrant gro up, responders took a total of  40 days of rescue medi cation, and non-responders to ok 
a total of 272 days. This confir ms that responders were positivel y affected by [CONTACT_838672]. When  
comparing the Vibrant and Sham groups, there was no overa ll significant diffe rence in rescue usage (p=0.5626).  
 
 
Summary results of Subgroup Analysis: 
For the moderate to severe patie nts, when using the endpoint CSBM  (increase of at least 1 CSBM/w eek for at least 6 out of 8 wee ks of 
treatment), the sham response rate is si gnificantly reduced, and the results reach signi ficance (35.1% vs . 15.0%, p=0.0307). Mu ltiple 
symptoms were significantly impr oved in the Vibrant arm, compared to sham: the Bristol Stool Score, st raining and bloating. The  
Vibrant Capsule showed two to three times the magnitude of effect of the sham on each  of these endpoints. Other subgroups (mild  
constipation and very severe constipation) were moderately improved for endpoints but were never nega tively impacted by [CONTACT_838673]: The Vibrant capsule found to be  safe and effective in sub- group (average weekly SBM _1.1 and <2.5 at baseline) com pared 
to sham.  
 
Additional study was planned for assess safety and efficacy in an increased administration (V-240) 
 
V-240: "A prospective, multicenter, random ized, double-blind, Sham-control led study to assess the ef ficacy and safety of the Vi brant 
capsule administered 5 times per week" 
The study was conducted in 25 sites in the [LOCATION_003] from Feb 2017 until Jan Dec 2017. 
 
Study design: This study is a prospective, adaptive, mu lticenter, randomized, double-b lind, Sham-controlled study  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 37 of 99 
 
 
 
Study objectives: the purpose of this study is  to assess the efficacy and safety of the Vibrant capsule administered 5 times pe r week. 
Study population: 182 Subjects with Functi onal Constipation refractory to existi ng treatments with an average of ≥1 and <3 
SBMs/week at baseline 
Endpoints: the primary endpoint were safety and efficacy.  
Safety: related AE's/SAE's 
Efficacy: an increase of at least [ADDRESS_1165082] 6 (of 8) weeks during the treatment period  
The secondary endpoints were:  
1. Change from baseline (run-in pe riod) in average straining. 
2. Change from baseline (run-in peri od) in average stool consistenc y, using the Bristol Stool Scale 
3. Change from baseline (run-in pe riod) in average bloating. 
4. SBM success rate, defined as an increase from the run-in peri od of at least one weekly Spontaneous Bowel Movement (SBM) 
during at least 6 of th e 8 weeks of treatment. 
 
Methods: 5 capsules / week for 8 weeks of treatment 
Results: A total of 88 Adverse Events (AE’s)  were reported in the active ar m and 50 in the sham arm. 2 AE’s were considered ser ious, 
1 in the Active arm - a traumatic fracture of pelvis considered not related and 1 in the Sham arm - anxiety attack considered n ot related.  
 
A summary of adverse events severity is provided below.  
  
  Vibrant Group Sham Group 
Number of 
reports Number of 
subjects IncidenceŦ Number of 
reports Number of 
subjects IncidenceŦ 
Any Adverse Event 88 37 41.57% 50 23 24.73% 
Mild 44 21 23.60%  26 16 17.20%  
Moderate 43 19 21.35%  24 14 15.05%  
Severe 1 1 1.12%  . . . 
  
The primary efficacy endpoints results are: –  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165083] 1 additional CSMB from baseline: 26.4% vs. 35.8% in the active arm and sham arm, respectively (ITT).  
2. At least 2 additional CSMB from baseline: 17.9% vs. 28.2% in the active arm and sham arm, respectively (ITT). 
 
According to the response rate of additional 1CSBM in this study, the increase of the administration frequency to 5 capsules pe r week 
contribute to the sham group (35.9%) while the active group  shows 26.9 % of responder's rate (I TT). The data indicates that the 
Vibrant sham (i.e., Vibrant capsule without vibrations) is an active cont rol, not a placebo. The Vibr ant sham performs better t han 
would be expected for a passive control. Th e capsule shape, size, and persistence in th e GI tract is part of the Vibrant therap eutic 
effect in addition to the vibration  
 
An important pattern was found between Freque ncy of CSBM and the actual time of vibr ation during the day. The pattern is import ant 
to understand the mechanism of action of th e Vibrant capsule and its effect on SBM/CS BM. A clinical correlation was found in th is 
study between the time of vibrati on and CSBM (graph 1).  CSBM frequency is higher  in the active arm comp ared to the sham arm 
during vibrating time as shown in  the graph, and exactly correlated to the time of  vibration as preprogr ammed for the capsule ( 1st 
peak) around 8-[ADDRESS_1165084]  is shown again 24 hours after activation of  same 
capsule (2nd peak around hour 34-36) and suggest that there is a re sidual effect of the capsu le vibration, (graph 1).  
 
Subjects in the sham group can be clearly identified in their behavior, as they repor t CSBM immediately after capsule swallowed  (time 
0 in the above graph). In addition, the sham response drops dr amatically the next morning, ( hours 34-36), as no additional caps ule was 
administrated that morning, while Vibrant active arm is showing superiority during th at time ([ADDRESS_1165085] vibration). 
The benefit to subjects during vibration time  is clearly shown in the graph below. The percentage of CSBM is higher in the acti ve group 
than in the sham group, during vibration time (see Vibrant edge in graph 2)  
 
Graph 2 Correlation between vibration and CSBM 
 
Conclusions: 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 39 of 99 
 
 
 
 Clean safety profile was maintained as in the previous studies. 
 Minimal AEs were reported during the 8 weeks of treatment, and a ll those reported were eith er mild or moderate. 
 A clinical correlation was found in this study between the time of vibr ation and Frequency of CSBM.   
 CSBM frequency during the capsule's vibrating time is higher for active arm compared to the sham arm, and exactly correlated 
to the time of vibration and near vibr ation time, as preprogra mmed for the capsule around 8- 12 hours from admin istration. 
 
An additional study (V-300) was planned to assess safety with active capsules in 2 di fferent operation modes. The total vibrati on time 
of the active capsules will be increased comp ared to the previous study and the vibrati on occurs in various areas of the colon (multi 
vibration sessions)  
 
 
 
 
 
 
V-300: " A prospective, multicenter, random ized, double-blind, sham-control led pi[INVESTIGATOR_838655] e efficacy and safety of  various 
vibrating capsule modes" 
 
The study was conducted in 2017- 2018. The enrollment period star ted on 14/Nov/[ADDRESS_1165086] on 14/March/2018.  
Study design: the study is a prospective, adaptive, multicenter, randomized, double-bl ind, Sham-controlled pi[INVESTIGATOR_799]. This is  a 3- 
arm study: 2 active capsule arms (mode 1 and 2) vs. a sham capsule arm. 
Study objectives: to assess Safety and efficacy of the Vibrant capsule  administered 5 times per week 
Study population: 63 Subjects with Functi onal Constipation refractory to existi ng treatments with an average of ≥1 and <3 
SBMs/week at baseline. 
Endpoints: the primary endpoint were safety and efficacy.  
Safety: related AE's/SAE's 
Efficacy: an increase of at least [ADDRESS_1165087] 6 (of 8) weeks during the treatment period  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 40 of 99 
 
 
 
Methods: The administration was 5 capsules/we ek.  The administration regimen was 1 cap sule/day on Mondays, Tuesdays, Thursday, 
Fridays and Saturdays and 2 days off (S undays and Wednesdays). On Jan 11th 2018 an amendment was approved and the weekly 
capsule administration regimen was cha nged from 5 per/week to 2 per/week. 
 
Results: The results presented are from subjects treated with 5 capsules/week.  
Safety: A total of 8 and Adverse Events (A E’s) in mode 1 and 2, and 4  in the sham  arm. None of the subjects experienced 
SAE's or adverse events rela ted to the Vibrant Capsule th at required discontinuation.  
Efficacy: In this study, the active capsule used has multiple vi bration sessions compared to si ngle vibration session in the V2 [ADDRESS_1165088] of multiple vibration 
sessions on the responder's rate. Improvement  by [CONTACT_2669] 1 CSBM - 75% of treatme nt weeks: 71.43% and 33.33% vs. 50% in 
Active mode 1, mode [ADDRESS_1165089]. The improvement form baseline in SBM/CSBM by [CONTACT_2669] 1 is hi gher 
in the vibrant capsule (mode 1 and 2) than in sh am capsule for administra tion of 5 capsules/week:  
a. SBM - 50% vs. 47.6% vs. 36.3% in Mode 1, mode 2 and sham, respectively for 5 capsules/week.  
b. CSBM - 50% vs. 38.1% vs. 31.8% in Mode 1, mode 2 and sham, respectivel y for 5 capsules/week.   
 
In this study the expected correla tion between vibration and near vi bration time and frequency of CS BM repeated itself, as in t he previous 
study (V-240). The capsule used was pre-prog rammed with multiple vibrat ion session. Hence, 2 peaks are shown: 1st peak around 8 -12 
hours from administra tion followed, a 2nd peak is shown around evening time (graph 3) 
 
 
Graph 3 - Correlation between vibration and freq uency of CSBM – multiple vibration sessions 
 
Conclusions: 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 41 of 99 
 
 
 
1. The active capsule found to be safe, even with an increased frequency of vibration (in the 2 different m odes), the treatment 
does not result with side effects and retains a very strong safety profile. 
2. The results indicate that multiple vibrat ion sessions improves efficacy and thus the percentage of CSBM was higher in the 
active arm (mode 1) than in the sham arm. 
3. Vibration dose, as an active ingredient to treat CIC patients, is shown to be mo re effective with patients in V-300 study, 
compared to administration of  5 cap/ week with a single vi bration session (lower dose of  vibration), in V-240 study.  
4. Mechanism of action is well in dicated in V-300 study (capsule with multiple vibration sessi ons. Hence, 2 peaks are shown 
around vibration time), whereby [CONTACT_838674], compared to sham arm. 
5.  The Vibrant capsule stimulates the existing natural mechanism of  the GI tract, in a mechanical  stimulation fashion only, which  
is different from a drugs, thus no related side-effects are found for th e treatment with vibrating capsule 
 
 
12. STUDY	OBJECTIVE 	
 
The objectives are to assess the effi cacy and safety of Vibrant capsu le administered 5 times per week. 
 
13. STUDY	ENDPOINTS 		
 
13.1 Primary endpoint 
Efficacy:   
The two primary efficacy endpoints are the CSBM [ADDRESS_1165090] one we ekly 
Complete Spontaneous Bowel Movement (CSBM)  during at least [ADDRESS_1165091] two weekly Comple te Spontaneous Bowel Movement (C SBM) during at least 6 of the 8  
weeks of treatment.  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 42 of 99 
 
 
 
The study will be deemed successful if eith er the CSBM1 or the CSBM2 success rate is  statistically significantly higher in the active 
arm that was continued after the inter im analysis, than in the placebo arm. 
 
 
NOTE:  
• A spontaneous bowel movement (SBM) is defi ned as a bowel movement that occurs at l east 48h after laxative/rescue intake and wit hout 
digital maneuver. 
• A complete spontaneous bowel movement (CSB M) is defined as a spontaneous bowel moveme nt associated with a feeling of complete 
evacuation by [CONTACT_423]. 
 
 
Safety Endpoints: 
• Safety endpoints include all adverse events related and unr elated to the study treatment 
 
13.2 Secondary endpoints 
Secondary efficacy endpoints include:  
• Change from baseline  in average straining. 
• Change from baseline in average stool c onsistency, using the Bristol Stool Scale 
• Change from baseline in  average bloating. 
 
Additional secondary efficacy endpoints include:  
• CSBM1 success rate when us ing the data from the two active arms together. 
• CSBM2 success rate when us ing the data from the two active arms together. 
• SBM success rate, defined as an increase from baseline of at least one weekly Spontaneous Bowel Movement (SBM) during at 
least 6 of the  8 weeks of treatment. 
• Incidence of Rescue Medication use during the treatment period 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 43 of 99 
 
 
 
• Change from baseline period in weekly numbe r of Spontaneous Bowel Movement (SBM). 
• Change from baseline period in we ekly number of Complete Spontan eous Bowel Movement (CSBM). 
• Rate of SBM ≤ [ADDRESS_1165092] dose 
• Change from baseline period in  average abdominal gas. 
• Change from baseline period in average abdominal pain. 
• Change from baseline period in abdominal discomfort. 
• Time to occurrence of spontaneous bowel movement after first capsule activation. 
• Treatment satisfaction score using the TSQM (Tr eatment Satisfaction Ques tionnaire for Medication) 
• Change from baseline in quality of life using the PAC-QOL  (Patient Assessment of Constipation Quality of Life) 
questionnaire.  
 
 
14. STUDY	CONDUCT 	&	POPULATION 		
 
This study will be performed in ac cordance with the design and specific provisions of this protocol, in accordance with the eth ical 
principles that have their orig in in the Declaratio n of Helsinki, that are consistent wi th Good Clinical Practice (GCP), Title 21 of the 
Code of Federal Regulations (21 CFR), part  812 (Investigational Device Exem ptions),  and the applicab le regulatory requirements . 
 
14.1 Inclusion Criteria 
1. Subjects aged 22 years and older 
2. Subjects with Chronic Idiopathic Constipation (CIC) according to  Rome III criteria and who have not experienced relief of 
their symptoms from available therapi[INVESTIGATOR_014] (osmotic and stimulant laxatives used for at least one month at recommended dose) 
3. Subjects with an average of ≤2.5 Spontaneous Bowel Moveme nts (SBM) per week and ≥1 SBM per week  
4. Normal colonoscopy performed within 5 years prior to study participation, unl ess the subjects are <50 years old and 
without alarm signs and/or symptoms 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165093] signed the Inform ed Consent Form (ICF) 
6. Female subjects must have a negative blood pregnancy test during screening, conf irmed by a negative urine pregnancy test 
during baseline and must not be lacta ting prior to receiving study medication. Fo r females of child-bearing potential, a 
hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of  birth control must 
be used throughout the study. All other female subjects must  have the reason for their inability to bear children 
documented in the medical record [i.e., tubal ligation, hysterectomy, or post-menopausal (defin ed as a minimum of one 
year since the last menstrual period)]; in these ci rcumstances, a pregnancy test  will not be necessary 
 
 
14.2 Exclusion Criteria 
1. History of complicated/obstr uctive diverticular disease 
2. History of intestinal or colonic obstruction, or suspect ed intestinal obstruction. 
3. History of significant gastrointe stinal disorder, including any form of inflammatory bowel disease or gastrointestinal 
malignancy (celiac disease is accepted if the s ubject has been treated and is in remission) 
4. History of gastroparesis 
5. Use of any of the following medications:  
 Medications that may affect intestinal motility, proki netics, anti-Parkinsonian me dications, opi[INVESTIGATOR_858], opi[INVESTIGATOR_2438], 
calcium-channel blockers, al uminum/magnesium hydroxide 
 With the exception of antidepressants, thyroid or hormonal replacement ther apy, when the subject has been on 
a stable dose for at least [ADDRESS_1165094] ocele, history of intestinal 
resection (with an exception for appendectomy, cholecystectomy and inguinal hernia repair), hist ory of bariatric surgery or 
evidence of any structural abnorma lity of the gastrointestinal tr act that might affect transit 
10. History of Zenker’s diverticulum, dysphagia, Barrett's esophagus, es ophageal stricture or achalasia 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 45 of 99 
 
 
 
11. Chronic use of non-steroidal anti-inflamma tory drugs (NSAIDs): chronic use is de fined as taking full dose NSAIDs more 
than three times a week for at least six months. Subjects on cardiac doses of aspi[INVESTIGATOR_152360]  
12. Subjects with pelvic floor dysfunction/defecatory disorder , based on subject history 
13. Participation in another clinical study within one month pr ior to screening. 
14. Women who are pregnant or lactating 
15. Use of any medication for constipation re lief during the study, except as rescue  medication, as indi cated by [CONTACT_207502] 
16. Inability to use an electronic daily Diar y (on a computer, phone application, tablet or other electronic device) to report bowe l 
movements, symptoms and medication usage 
17. Subject participated in a previous Vibrant study 
18. Subjects planning to under go MRI during the study 
19. Any known allergy to soybean or beeswax or Calcium Carbonate 
20. Any other condition which in the opi[INVESTIGATOR_838656] e safety of the subject or would limit 
the subject's ability to complete the study 
 
14.[ADDRESS_1165095] 10-11 we eks. 
The sample size is calculated fo r about 168 enrolled subjects (depending of the re sults of the sample si ze adaptation) includin g 10% 
drop-outs. 
Actual point of enrollment fo r the subject is considered th e day of first capsule intake. 
 
 
15. STUDY	TREATMENT 	
15.1 Study Design 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 46 of 99 
 
 
 
The study is a prospective, random ized, multi-center, double-blinded, placebo-controlled, 3- arm clin ical study to assess the e fficacy 
and safety of the Vibrant capsule, for the tr eatment of Chronic Idi opathic Constipation. 
 
The objectives are to assess the efficacy and safety of Vibrant capsule administered 5 times a week vs. Placebo in subjects wit h chronic 
idiopathic constipation. 
 
The study will be performed in about 30 centers in the [LOCATION_003]. 
 
Data reporting will be done on an electronic Case Report Form (e CRF). In addition, subjects will fill in daily information abou t their 
bowel movements, clinical symptoms and me dication usage on an electronic Diary (eDiar y). The eDiary will be accessed via a comp uter, 
smartphone, tablet or othe r suitable device, throu gh a designated website.  
Information about time of activation of th e Vibrant Capsules will be recorded auto matically by [CONTACT_688991] a designated website. 
 
 
Subjects with Chronic Idiopathic Constipation (CIC) according to Rome III criteria who failed currently available therapy (defi ned as 
osmotic and stimulant laxatives used for at  least one month at recommen ded dose) and meet the study inclusion and exclusion cri teria 
will be offered participa tion in this study. The background of the proposed st udy and its risks and benefits will be explained to the 
subject and the informed consent form will be signed prior to any study related procedures.  
 
Subject will come for 4 visits: Sc reening, baseline, after 4 weeks and after 8 weeks of treatment. 
 
During the visits, an interview will be c onducted, where the following topi[INVESTIGATOR_171212]: occurrence of adverse events, 
compliance to filling in the daily informa tion on the eDiary and to the treatment, co ncomitant medication/rescue taken, evoluti on of 
constipation symptoms, subject’s perceptions about the treatmen t, motivation of the subject, or  any other relevant topic. 
 
Subjects will take either Vibrant or Placebo capsule during 8 weeks: 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 47 of 99 
 
 
 
Three arms will be assessed:  
- Vibrant Capsule mode A administered [ADDRESS_1165096]'s home  (for more 
details see section 15.9).  
 
 
15.[ADDRESS_1165097]’s demographic and medical informati on acquired from the subject or  the subject's medical chart, including age, gender, 
weight, height, body mass index (BMI), number of natural childbirt h and previous medical history and medications will be record ed, 
including: a history of clinical ly significant abnormalities of all body systems; concurrent dise ases; relevant past medical hi story.  
The information will be recorded in the eCRF for all subjects participating in this study.  
15.[ADDRESS_1165098] ed on the eCRF, including duration of constip ation, full history and habits of medic ation 
(over the counter and prescriptio n) and supplements use, frequency of spontane ous bowel, current medi cation/supplements use, 
description of current diet (w ith focus on water intake and fi ber intake), physical activity (n umber of hours of physical activ ity per 
week), recent change in bowel movements. 
15.4 Physical Examination 
During the screening visit all subjects w ill undergo a conventional physical examinati on by [CONTACT_207530]. The physic al 
examination will include diagnosis and documentation of any signi ficant abnormalities or diseases . The physical examination wil l 
include a digital rectal examination. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 48 of 99 
 
 
 
15.5 Assessment of pelvic floor dysfunction (defecatory disorder) 
Assessment of pelvic floor dysfunction will be based on subject history. Subjects with suspi[INVESTIGATOR_838657]. 
If subjects have been previously diagnosed  with pelvic floor dysfunction following an orectal manometry, a balloon expulsion tes t, or 
other examinations, documented re sults from these tests can be used to exclude subjects.   
 
15.6 Blood and urine tests 
During the screening visit all subjects will undergo the follow ing blood tests: blood count, cal cium, creatinine, Blood Urea Ni trogen 
(BUN), sodium, potassium and TSH. Blood pregnancy test will be pe rformed during the screening vis it. A pregnancy urine test wil l be 
performed during th e baseline visit. 
 
15.7 Screening visit (day -21 to -14) 
Subjects will be asked to sign a consent form and will be screen ed for study eligibility according to inclusion and exclusion c riteria. The 
daily bowel movements frequency, history of  constipation, etiology of constipation and medication us e (including prescription 
medication) will be thoroughly assessed. Subject demographic and me dical information acquired from the subject or the subject's  
medical chart, including age, gender, previ ous medical history, concomitant medications, risk factors etc. will be also recorde d on the 
eCRF.  
 
The Bristol Stool Scale and Rome III questionnaire (see Appendix A,  B) will be completed by [CONTACT_941] i nvestigator to confirm the dia gnosis 
of Chronic Idiopathic Constipation.  Findings will be recorded on the eCRF. 
 
In addition, subjects will undergo a physic al examination including digital rectal ex amination, vital sign m easurements and blo od tests. 
PAC-QOL (see Appendix D) be completed by [CONTACT_688993]. 
 The investigator will confirm their eligib ility and their physical and mental suitabi lity to participate in this study.  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 49 of 99 
 
 
 
Eligible subjects will then be asked to refrain from taking any medication or supplement they ar e using to relieve their consti pation 
during the entire study period except as allowed under the protocol ( rescue treatment is allo wed as per section 15.12 ).  
 
Following the screening visit, s ubjects will enter the run-in period, in which an e-diary will be comple ted (on a daily basis) for 14 
consecutive days  (run-in period).  On the day of screening, the coordi nator should determine with the subj ect the last day of intake of 
constipation medication/aid and ensure that the last intake of constip ation medication/aid has been  taken more than [ADDRESS_1165099] will define his/her preferred device to use the eDia ry. The subject and study coordi nator will define together the time of the 
day during which the subject will fill in the eDiary and a dail y alert will be set up on the phone of the subject.  
 
Subjects exiting the trial at this stage w ill be considered screening failure subjects  and will be replaced with new subjects. 
 
15.8 Run-in period (day -21 or -14, to -1) 
Eligible subjects after screening, will be observed and monitored for the first [ADDRESS_1165100] day of run-in period.  
 
In the eDiary the subjects will be asked to report on their:  
• Daily BM,   
• Change of diet, if applicable (NOTE: the protocol will not ask th e pt to change anything in his/her diet. any change of diet wi ll 
be recorded in the eDiary)   
• Change in symptoms as: Bristol stool consistency, straining, bloa ting, and the other questions in the eDiary     
• Medication  
• AE/ change in general health condition  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 50 of 99 
 
 
 
The information will be transf erred to the eCRF every day.  
  
The run-in period may be extended by a few days in case of tec hnical issue (difficulty to access eDiary), to allow for a wash-o ut period, 
or other. The run-in period ma y be extended by [CONTACT_8622] [ADDRESS_1165101] an  average 
of ≥1 SBM and ≤2.[ADDRESS_1165102] 1 shor t phone call/week from the study coordinator.  
The phone calls will be about 5- [ADDRESS_1165103] understanding of what he/she needs to do in the context of the study and discuss any issue or dif ficulty 
that the subject might have. Confirma tion of date and time of the phone call will be reported on the eCRF. 
 
If a subject does not fill in hi s/her eDiary, the sponsor/investigator will be alerted and the subject will be contact[CONTACT_838675]. Compliance of the subj ect will be closely monitored. 
3 times or more of missing diary (not due to technical issues) dur ing the run-in period, may be considered as screening failure s due to 
lack of compliance. 
15.9 Baseline / randomization visit (day 0) 
 
After the run-in period, if subject is found eligibile for randomization,  he/she will be  invited to the medical center for the  baseline visit 
for further assessment. Eligibility will be  re-assessed and confirmed ba sed on Rome III questionnaire  and the subject's eDiary.  
 
Eligible subjects will be randomized to either Vibrant mode A or  Vibrant mode B or Placebo arm (1:1:1 ratio), for a treatment p eriod of 
8 weeks.  
 
The subjects will be trained in the medical center how to use th e base unit. He/she will activate the first capsule and will in gest it in front 
of the medical staff. All other capsules will be ingested at the subject' home.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165104] the capsules 5 days per w eek: one capsule on Mondays, Tuesdays, Thurs days, 
Fridays and Saturdays (total of 40 capsules  for the whole study). Subjec ts will not ingest any caps ule onWednesdays, and Sunday s.  
If the visit falls on a Sunday or Wednesday, the subject should ingest the first ca psule on site and skip the next day.  
 
Actual point of enrollment fo r the subject is considered th e day of first capsule intake. 
The first [ADDRESS_1165105] s’ training period. 
 
During the visit, an interview will be c onducted, where the following topi[INVESTIGATOR_838658]: occurrence of adverse events, 
compliance to filling in the daily informa tion on the eDiary and to the treatment, co ncomitant medication/rescue taken, evoluti on of 
constipation symptoms, subject’s perceptions about the treatment, motivation of the subject, or an y other relevant topic. In ad dition, 
the subject will receive capsule s supply for Treatment period 1 (period of 4 weeks between baseline and next visit).  
 
During treatment period 1, Subjects will be instructed to continue  filling a daily eDiary. This will include daily recordings o f capsule 
intake, number and time of bowel moveme nts, clinical symptoms score, AEs/ change in their health condition , and 
medication/supplements usage, including rescue medication. 
 
 
15.10  4 weeks visit (day 28 ± 2) 
 
Four weeks after baseline visit, an on-s ite visit will be conducted to evaluate subject's treatment efficacy and safety.  
 
During the visit, the following topi[INVESTIGATOR_688974] : 
 
 subject's safety (including AE/ ch ange in general health condition) 
 eDiary completion  
 compliance with capsules intake 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 52 of 99 
 
 
 
 concomitant medication/re scue administration 
 evolution of constipation symptoms 
 device accountability: at [ADDRESS_1165106] bring back to the site all remaining capsules (including spare capsule) i n 
his/her possession and the capsules must  be counted and accounted for. 
 motivation of the subject, or  any other relevant topic . 
 
In this visit the subject will receive capsules supply for Treatm ent period 2 (period of 4 weeks between this visit and termina tion visit).  
 
During treatment period 2, Subjects will be inst ructed to continue  filling a daily eD iary. This will include daily recordings of capsule 
intake, number and time of bowel moveme nts, clinical symptoms score, AEs/ change in their health condition , and 
medication/supplements usage, including rescue medication 
   
 
15.11  8 weeks visit / Termination (day 56 ± 2) 
Eight weeks after baseline visit, an on-site visit (fina l visit) will be conducted to evaluate the following: 
 subject's safety (including AE/ cha nge in general health condition).  
 eDiary completion  
 concomitant medication/re scue administration 
 evolution of constipation symptoms 
 device accountability: At 8W visit, subject must bring back to th e site the base unit and the router as well as all remaining 
capsules in his/her possession and the capsule s must be counted and accounted for. 
 PAC-QOL ,TSQM and ease of use questionnaires 
 
 
15.12  Rescue Treatment 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165107] the investigator prior to taki ng any medication/supplement but they will be  
required to declare all the rescue medi cation on their eDiary. The following treatment is reco mmended (not by [CONTACT_75775]): 
1. Dulcolax® (bisacodyl) suppository 
2. Fleet Enema® 
3. Dulcolax® (bisacodyl) tablet (1x5mg) 
 
The subject is allowed to take a rescue medication/supplement that  is not in the above list, wi thout contact[CONTACT_838676] r. The 
subject must declare all resc ue intake in the eDiary. 
 
Subjects who take rescue medicat ion three times or more  during the run-in period will be considered as screening failures. 
 
 
15.[ADDRESS_1165108] be documented in the case report form (name [CONTACT_838692], date of intake, dosage, number of takes 
per day, reason for medication). The subj ect will fill in all the information in the eDiary on a daily basis.  
 
 
15.14  Prohibited medication 
The medications listed below will be prohibited during the entire study:  
- Medications that may affect intestinal motility  
- Prokinetics 
- Opi[INVESTIGATOR_838659] V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 54 of 99 
 
 
 
- Opi[INVESTIGATOR_2438] 
- Calcium-channel blockers 
- Aluminum/magne sium hydroxide. 
 
 
Chronic use of non-steroidal anti -inflammatory drugs (NSAIDs) is also prohibite d. Chronic use is define d as taking full dose NS AIDs 
on a regular basis (i.e. more than three times a week) for at least six months.  
Subjects on cardiac doses of aspi[INVESTIGATOR_27969] n may be enrolle d in the study.  
 
The following medications are equally prohibit ed, but with an exception when the subject  has been on a stable dose of the medic ation 
for at least 3 months: 
- Antidepressants 
- Thyroid or hormonal re placement therapy. 
 
 
 
15.[ADDRESS_1165109] will be questioned on his/her clinical status, the pr esence of any medical intervention performed since the last vi sit and 
any adverse events or discomforts. When necessary, the subjec t will be asked to arrive for a follow-up visit at the clinic. 
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 55 of 99 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
15.16  Study Schedule   
Table 1 summarizes the required data collection from assessme nts and tests perfor med during the study. 
 
 
Procedures Screening Baseline 4w visit  8w visit 
(Termination)   
  
Visit No.  1 2 3 4   
Day -21 to -14 0 28 (±2 days) 56 (±2 days)   
IC +      
Eligibility Criteria  + +     
Physical Exam  +      
Digital Rectal Exam  +      
Vital Signs  +      
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165110]  +      
Urine Pregnancy test (if 
applicable)  +     
Administration of 
capsule   +     
Rome III  + +     
Bristol Stool  +      
PAC-QOL +   +   
TSQM & Ease of use    +   
Subject eDiary  + + + +   
Adverse Events   + + +   
Device accountability   + +   
Concomitant Medication  + + + +   
Table 1  – Study Schedule of Assessments 
 
15.17  Deviations from study protocol 
 
Any deviation from the study protocol should be notified to the sponsor, documented on study deviation forms and reported to th e Ethics 
Committee as required. 
 
Protocol deviations related to treatme nt compliance (e.g. missed capsu le, capsule taken on a non-cap sule administration day, et c.) will 
not be declared on the protocol deviation form accessible via the EDC (Electronic Data  Capture). Protocol deviations related to  treatment 
compliance will be monitored and declared by [CONTACT_1034], CRO and sites using a platform external to the EDC. This external pla tform 
will use the information transmit ted from the base units about act ivations (base unit serial numb er, date and time of activatio n, 
success/failure) as a basis to monitor treatment compliance. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165111] will be consid ered equivalent as protocol  deviations forms. The site  will not manually enter thes e protocol 
deviations in the EDC. 
 
15.18  Investigative Center Selection Criteria 
 
The investigative site will meet the following selection cr iteria prior to incl usion in this study: 
 Clinical research study expe rience and resources that de monstrate good compliance with  study requirements and timely, 
complete documentation of subject follow-up.   
 Sufficient subject volume to meet enrollment timeframe. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 58 of 99 
 
 
 
16. ADVERSE 	EVENTS	RECORDING 	
 
At each evaluation, the investigator will dete rmine whether any adverse events (AE’s) ha ve occurred. All adverse events occurri ng 
during the study will be recorded on the ap propriate case report form pa ge and signed by [CONTACT_093].  The nature, severit y and 
relation of the adverse event to the study device will be documented.  
16.1 Reporting Requirements 
Timely and complete reporting of Adverse Ev ents (AE) and safety assessment allows: 
 Protection of safety  and study subjects. 
 Greater understanding of th e overall safety profile of the study treatment. 
 Appropriate modification of st udy protocols and improvement in  study design and procedures. 
 Adherence to regulatory requirements. 
The definitions and reporting requirements adopted in this study are de rived from the current Intern ational standard on clinica l 
investigations: Title 21 of the Code of Federal Regulations (21 CFR), part 312 (Inve stigational New Drug Application), Section 32 (IND 
Safety Reporting) and part 812 (Investigationa l Device Exemptions), Section 150 (Reports). 
16.2 Definitions  
Adverse Events (AE) 
AE is defined as any untoward medical occurrence in a subject. This definition does not imply that there is a relationship betw een the 
adverse event and the device under i nvestigation.  An AE can therefore be any unint ended sign, symptom, disease or injury or an y 
untoward clinical signs (including an abnor mal laboratory findings) in subjects, users or other persons whether or not related to the 
investigational medical device. The following should be reported as AE: 
 Untoward medical conditions or si gns or symptoms that were abse nt before starting study treatment. 
 Untoward medical conditions or signs or symptoms present befo re starting study treatment and wo rsen (increase severity or 
frequency) after star ting study treatment. 
 Abnormal laboratory findings. 
 Clinical signs or symptoms that require therapy. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165112] (ADE) 
ADE is adverse event, related to the use of an investigational medical device. This  includes any advers e event resulting from 
insufficiencies or inadequacies in the instructions for use or the deployment of the device, the operation, or any malfunction of the 
investigational medical device, device failure or misuse,  and any event that is a result of a user error. 
 
Device failures, Malfunctions and Misuse 
Investigators are instructed to report a ll possible device failures or misuse observe d during the course of  the trial. These in cidents will 
be documented in the case repor t form provided as follows: 
 
 Device Failure  - A device failure has occurred when the device is used in compliance with the Inst ructions for Use, but does 
not perform as described in th e Instructions for Use. A de vice failure occurs when  
o A capsule fails to activate.  
o The transmission about the first capsule activation cannot be perform ed (during the baseline visit) by [CONTACT_207537]. 
This event must lead to the re placement of the base unit.  
o The base unit loses its ability to trans mit information permanently. This event must  lead to the replacement of the base 
unit. 
Device Misuse  - Any use of the investigational devi ce by [CONTACT_688996].  
 
 
Serious Adverse Events (SAE) 
A SAE is an adverse event that: 
1.     Led to a death, 
2.     Led to a serious deteriorati on in the health of the subject that: 
a. Resulted in a life-threatening illness or injury 
b. Resulted in a permanent impairment of  a body structure or a body function 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165113] atform, and signed by [CONTACT_779].  
 
 
Device deficiencies that might ha ve led to a SAE if a suitable action had not been  taken or intervention had not been made or i f 
circumstances had been less opportune are al so handled under the SA E reporting system.  
However, planned hospi[INVESTIGATOR_5912]-exis ting condition and/or procedur e required by [CONTACT_625891], without s erious 
deterioration in health, is not  considered to be a SAE. 
 
Serious Adverse Device Effect (SADE) 
A Serious Adverse Device Effect is an adve rse device effect that has re sulted in any of the conseque nces characteristic of a se rious 
adverse event. 
 
Unanticipated Serious Adv erse Device Effect ([LOCATION_003]DE) 
[LOCATION_003]DE is defined as serious adverse device effect which by [CONTACT_5942], incidence, seve rity or outcome has not been identified i n the 
current version of the risk analysis report or other study related documents.  
 
16.3 Anticipated Adverse Events 
The Vibrant Capsule targets pat hophysiological parameters of ch ronic constipation by [CONTACT_838677]. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 61 of 99 
 
 
 
Anticipated Adverse Events include those that are reasonably exp ected to occur in association wi th a clinical investigation ass essing a 
treatment for Chronic Idi opathic Constipation. Events can occu r as a result of the di sease or as a result of the treatment (inc luding 
usage of the home base unit). They may include but are not limited to the following (in al phabetical order): 
 Abdominal pain/discomfort/crampi[INVESTIGATOR_007] 
 Blood in the stool may develop or increase 
 Bloating/Flatulence 
 Diarrhea  
 Nausea may develop or increase 
 Rectal pain may de velop or increase 
 Sensation of vibration in the abdomen 
 Uncontrolled leakage of stool may occur 
 Vomiting may develop 
 
All events listed above, and additional ev ents that the investigator will evaluate will fit the definition of ‘anticipated even t’, will be 
categorized as such in the study. 
16.[ADDRESS_1165114] be  recorded on the appropriate AE form i n the 
eCRF, within a reasonable time (up to 5 calendar days from investigator's awaren ess of the event). All AEs will be characterize d by 
[CONTACT_4868]: 
 Intensity or Severity 
 Relatedness 
 Outcome 
 Treatment or Action Taken. 
 
16.4.1  Intensity or Severity 
The following categories of the intensity of  an adverse event are to be used:  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 62 of 99 
 
 
 
Mild  – Awareness of a sign or symptom that does not interfere with th e subject’s usual activity or is  transient, resolved without 
treatment and with no sequelae. Moderate  – Interferes with the subject’s usual activity and/or requires symptomatic treatment. 
Severe  – Symptom(s) causing severe discomfort  and significant impact of  the subject’s usual activity and requires treatment.  
16.4.2  Relatedness 
The investigator will use the following definitions to assess th e relationship of the AE to the investigational medical device:  
Not related  - The cause of the AE is known and the event is not related to the inves tigational medical device. 
Possibly related  - There is a reasonable possibility that the event may have been caused by [CONTACT_207541]. 
The AE has a timely relationship to the st udy procedure(s); however, follows no known pa ttern of response, and an alternative c ause 
seems more likely or there is  significant uncertainty about  the cause of the event.  
Probably related  - It is likely that the event was cau sed by [CONTACT_207541]. 
The AE has a timely relationship to the study procedure(s) and follows  a known pattern of response ; a potential alternative cau se, 
however, may explain the event. 
Related  - A related event has a strong temporal rela tionship and an alterna tive cause is unlikely. 
 
16.4.3  Outcome 
The clinical outcome of the AE or SAE will be characterized as follows: 
Death  - The SAE CRF must be completed for this outcome (see section 16.5 Expedited Reporting of Serious Adverse Events). 
Recovered without sequelae  - The subject has recovered with no sequelae from the event 
Ongoing  - Subject did not recover and symptoms continue 
Recovered with sequelae  - The subject has recovered but wi th clinical sequelae from the event 
Unknown  - The subject outcome is unknown 
 
16.4.4  Treatment or Action taken 
The treatment or action taken after the occurrence of an AE or SAE will be reported as: 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 63 of 99 
 
 
 
Interventional Treatment  - Surgical, percutaneous or other procedure 
Medical Treatment  - Medication frequency of administra tion reduction/interruption or discontin uation, or medicati on initiated for 
event 
None  - No action is taken 
 
16.5 Expedited Reporting of Serious Adverse Events 
Any Serious Adverse Event, and device deficiencies should be repor ted to Vibrant Ltd. within 24 h ours of investigators' knowled ge of 
the event. Investigator should report these events on the appropri ate SAE form / Device Deficienci es Form in the eCRF and send the 
form by [CONTACT_3719] e-mail, to the fo llowing safety contact [CONTACT_9702]: 
 
Lior Ben Tsur 
Vibrant 
Hakochav 
Yokneam 2069206 
[PO_BOX], Israel 
Tel: [PHONE_9731] 
Cell: + 972-54-6950001 
[EMAIL_4062]  
 
If applicable, the investigator should also inform the represen tative of the appropriate local Ethics Committee, within 24 hour s of 
investigator's awareness of the even t. A copy of the report co ver letter should be filed within the study file.  
  
The sponsor is responsible for the ongoing sa fety evaluation of the inve stigational medical device. The sponsor will promptly n otify 
all concerned investigator(s)/in stitution(s) and the regulatory authority(ies) of findings that could affect adversely the safe ty of 
subjects, impact the conduct of the trial, or alter the Medical Ethics Committee approval/favorab le opi[INVESTIGATOR_838660]. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 64 of 99 
 
 
 
The sponsor will expedite the reporting to all concerned investig ator(s)/institutions(s), to the EC(s), where required, and to the 
regulatory authority(ies) of the occurrence of Unanticipated Serious Adverse Device Effects.  
 
16.6 Follow- Up of Unresolved Events 
All adverse events should be followed  until they are resolved or the subjec t’s participation in the study ends.  
	
17. STATISTICAL 	CONSIDERATIONS 		
17.1 Study Design and Objectives 
 
The study is planned as a prospective, ra ndomized, multi-center, double-b linded, placebo-controlled, 3- arm study, designed to assess 
the efficacy and safety of Vibrant capsule vs. placebo, for the treatment of chronic idiopathic constipation. 
  
After a run-in period of 14-21 days , subjects will be randomized with a ratio of 1: 1:[ADDRESS_1165115] 
2 weeks of treatment will be considered as a subjects’ training period. One interim an alysis will be conduc ted after about [ADDRESS_1165116] one w eekly 
Complete Spontaneous Bowel Movement (CSBM)  during at least 6 of the 8 weeks of tr eatment, and CSBM2 success rate, defined as 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165117] two weekly Comple te Spontaneous Bowel Movement (C SBM) during at least 6 of the 8  
weeks of treatment. 
 
The study will be deemed successful if eith er the CSBM1 or the CSBM2 success rate is  statistically significantly higher in the active 
arm that was continued after the inter im analysis, than in the placebo arm. 
 
17.2.2  Secondary Efficacy Endpoints 
Secondary efficacy e ndpoints include:  
1. Change from baseline in average straining 
2. Change from baseline in average stool c onsistency, using the Bristol Stool Scale  
3. Change from baseline in  average bloating. 
17.2.3  Additional Efficacy Endpoints 
Additional secondary efficacy endpoints include: 
- CSBM1 success rate when us ing the data from the two active arms together . 
- CSBM2 success rate when us ing the data from the two active arms together.   
- SBM success rate, defined as an increase from baseline at least one weekly spont anuous Bowel Movement (SBM) during at 
lease 6 out of 8 weeks of treatment.  
- Incidence of Rescue Medication use during the treatment period. 
- Change from baseline in weekly number of  Spontaneous Bowel Movement (SBM). 
- Change from baseline in weekly number of Co mplete Spontaneous Bo wel Movement (CSBM). 
- Rate of SBM ≤ [ADDRESS_1165118]  capsule activation. 
- Treatment satisfaction score using the TSQM (Tr eatment Satisfaction Ques tionnaire for Medication) 
- Change from baseline in quality of life using the PAC-QOL  (Patient Assessment of Constipation Quality of Life) 
questionnaire.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165119]  the following hypotheses: 
 H0 : P a1-Ps1=0 
 H1: Pa1-Ps1≠0 
Where P a1 is the CSBM1 success rate in the selected active arm, and P s1, the CSBM1 success rate in the placebo arm. 
AND: 
 H0 : P a2-Ps2=0 
 H1: Pa2-Ps2≠[ADDRESS_1165120] th e null hypothesis. Calculations (using SAS® proc power) show that a sa mple size of 150 subjects 
(60 in the 2 study arms that will be c ontinued till the end of the study, and 30 for the study arm that will be dropped at the interim 
analysis), would provide 80% power at  a st udy wise 5% level of significa nce (two-sided), i.e. 2.5% for each one of the primary  
endpoints to detect a difference of 25% in the success ra te, assuming a success rate of 15% in the placebo arm.  
The sample size will be increased to at le ast 168 subjects (67 in the 2 study arms th at will be continued till the end of the s tudy, and 34 
for the study arm that will be droppe d at the interim analysis to account for a potential 10% of drop-out rate. 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165121] as appropriate for the statistical h ypothesis. 
ONLY the un-blinded statistician and members of the DSMB committee will be exposed to  the report. Investigators and company 
directors will only be informed of  a decision to continue or to discontinue the trial, or to implement modifications in sample size 
increase. 
 
17.5.1      Procedure 
After all the relevant data will be entered into the database, a nd the database cleaned, a soft lock to the database will be pe rformed. An 
independent un-blinded statistician (not the study stat istician) will perform the assessments described below. 
At the interim analysis, the data of th e evaluable subjects will be analyzed.  
 
17.5.2  Blinding 
ONLY the un-blinded statistician will be exposed to the subjects’  treatment allocation. Investigators and company directors wil l only 
be exposed to the interim report. 
The members of the DSMB (Data and Safety Monitoring Committe e) may also have access to th e unmasked information of the 
interim analysis. Investigators and company di rectors will only be informed of a decisi on to continue or to discontinue the tri al, or to 
implement modifications in samp le size of the trial. The un-b linded statistician who is respons ible for conducting the interim analyses 
should ensure that the unmasked data is not available to any unauthorized person within or out side the company. 
17.5.3  Decision Rules 
The purposes of the interim analysis are: 
 to select the most promis ing vibrations regimen (dr op-the-loser design), and 
 to re-assess the sample size based on conditional power.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165122] promising vibrations reg imen will be selected, and then the followi ng will be performed for this study arm. 
The study will either continue to the originally planned sample si ze if the result is “favorable”,  stop for futility if the res ult is 
“unfavorable”, or an increase will be made  to the sample size if the result is “pro mising”. These decisions  will be made based on the 
conditional power (CP), defined as the conditional probability that  the result will exceed a crit ical value at the interim give n the 
observed effect size   𝛿ଵ෢  = difference between CSBM success rates active versus placebo at the interim look.  
Notation: 
n1= sample size at interim analysis  (30 subjects in each study arm). 
n2= original sample size calculated based on assumed effect size (168). 
nmax = the highest sample size the co mpany is willing to use, nmax = 600 (including allowance for drop-out). 
CPmin=is the calculated minimum CP based on the ratios nmax/n2, n1/n2 and the target study power (80%). 
The following are the decision rules for the in terim analysis. These depend on the zone into which CP falls at the interim, the  
calculated CPmin, the maximu m sample size designated for the st udy and the % of the orig inally planned sample size at which the  
interim analysis will be performed. Following this  principle does not infl ate the Type I error. 
1. If the respective conditional power for each of the primary endpoi nts is < 26.97% or if the diff erence between the success rate  
(treatment –placebo) for both prim ary endpoints is less than 10%, th en stop the trial for futility.  
2. a. If the conditional power for both primary endpoints is 26.97% ≤ CP < 80% then recalculate the samp le size to recover the targeted 
80% for both endpoints, the maximum sample si ze selected will be th e larger of the two.  
b. If the CP of only one of the primary endpoints is 26.97% ≤ CP < 80% then recalculate the sample size to recover the targeted 
80% for that endpoint alone.  
In both cases a and b, the maximum sample  size for the study will be 600 subjects  
3. If the respective conditional power for each of the primary endpoints is ≥ 80% then continue to the originally planned sample size.  
Note that the interim an alysis will be conducted on both the ITT and mITT anal ysis sets, and the study will be stopped due to f utility 
only if the interim effects in both po pulations fall below the threshold. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 69 of 99 
 
 
 
17.5.4   Controlling the Alpha level for the primary endpoint 
The overall alpha level for this study is 5%. According to refere nces 26-28, planning an  interim analysis that permits an incre ase in the 
sample size as described above doe s not inflate the type I error. 
 
17.[ADDRESS_1165123] meets the eligibility criteria, he/she will be equally allocated (with a 1:1:1 ratio) to one of the following t reatment groups 
based on a randomization scheme with randomiz ed blocks’ size stratified by [CONTACT_384]:  
 Vibrant capsule mode A admin istered 5 times per week 
 Vibrant capsule mode B admin istered 5 times per week 
 Placebo capsule administered 5 times per week 
The randomization scheme will be pr epared by [CONTACT_207543]® (version 9.4.) random numb er generating procedure. 
17.[ADDRESS_1165124]. 
17.8 Data Analysis Sets 
17.8.1  Intent to Treat (ITT) 
The ITT analysis set will consist of all subjects randomized. In accordance with the ITT principle, all subjects randomized wil l be kept 
in their originally assigned treatment group for analysis. Subj ects with no valid post baseline assessment will not be part of the 
relevant analysis. 
17.8.2  Modified Intent to Treat (mITT) 
The mITT analysis set will consist of all ra ndomized subjects who met the inclusion cr iteria of the protocol. In accordance wit h the 
ITT principle, all subjects randomized w ill be kept in their originally assigned treatment group. Subjects with no valid post b aseline 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 70 of 99 
 
 
 
assessment will not be part of the relevant analysis. Subjects with less than 2 weeks (with at least 5 days per week) of valid diary 
during the treatment period will be  considered as non-evaluable 
17.8.3  Per-Protocol (PP) 
The per-protocol analysis set will consist of all subjects from the mITT analysis set w ithout major protocol violations and suc cessfully 
completed the study, with treatme nt group analyzed as treated. 
17.8.4  Statistical Analysis of Analysis Sets 
The ITT analysis set will serve as the main set for safety assessments . 
The mITT analysis set will serve as th e main set for efficacy assessments . 
 
The efficacy assessment will be presen ted on the ITT and PP analysis sets . 
17.9 Statistical Analysis 
17.9.1  General Considerations 
Statistical analyses will be performed using SAS® v9.4 or higher (SAS Institute, Cary NC, [LOCATION_003]). 
Baseline demographic and other baseline characteristics, together with safety analyses will be performed on all enrolled subjec ts. 
Baseline values are defined as the last valid value prior to treatment . 
All statistical tests will be two-sided.  If statistical tests are performed nominal p-values will be presented. Where confiden ce limits are 
appropriate, non-adjusted two-sided 95% c onfidence interval will be constructed . 
For comparison of means (continuous variables), the two-sample t-test  or the Wilcoxon rank sum test will be used as appropriate .  For 
comparison of proportions ( categorical variables), th e Chi-squared test or Fisher’s exact test will be used as appropriate . 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 71 of 99 
 
 
 
17.9.2  Significance levels and handling of type I error 
[IP_ADDRESS]  Type I Error 
The overall significance level for this study is 5% using two-tailed tests. According to references 26-28, planning an interim analysis 
that permits an increase in th e sample size as described in section 17.5 does not inflate the t ype I error. The treatment by [CONTACT_838678]  a significance level of 10%.  
[IP_ADDRESS]  Primary Endpoints 
The primary endpoints for the dropped  study arm will not be analyzed. 
The Benjamini and Hochberg technique for co ntrolling the false discovery rate will be implanted fo r the two prim ary endpoints. 
[IP_ADDRESS]  Hierarchy Approach for Secondary Endpoints Analysis 
The hierarchy approach will be adopted for the primary and sec ondary endpoints to control type I error due to multiple endpoint s 
testing. Thus, the primary endpoint will first be analyzed and only if one of them is  found statistically si gnificant, will the  secondary 
endpoints be analyzed.  
The first secondary endpoint will be tested, first, for st atistical significance a nd only if found significant (versus an alpha  level of 5%), 
the next in line will be tested. Only if the first and second secondary endpoints are found statistically significant, then the  third one 
will be tested, and so on. 
The order of the secondary endpoint s is as listed in paragraph 17.2.2. 
  
17.9.[ADDRESS_1165125] deviation, minimum, median and maximum, a nd categorical variables by a count and percentage . 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165126]’s CSBM1 success status (i.e. if the subjects achieve an increase from baselin e of at least [ADDRESS_1165127] 6 
out of the 8 treatment weeks) wi ll be presented in tabular fo rm by [CONTACT_30157], along with 95% Wi lson score Confidence Intervals (CI) 
and will be compared between the st udy arms with a Cochran-Mantel-Haen szel test controlling for center. 
 
The CSBM2 and SBM success rates will be  analyzed in a similar manner. 
 
The incidence of rescue medication and the rate of SBM within [ADDRESS_1165128] study dose use will be analyzed in a simi lar 
manner. 
 
The change from baseline in average straini ng will be modeled with an Analysis of C ovariance (ANCOVA) m odel, with baseline 
average straining and site entered as cova riates. The adjusted means of the change from baseline per study arm, and the differe nce 
between the groups will be presented along with  respective 95% CI. The change from baseli ne in average stool consistency, in av erage 
bloating, in weekly number of SBM and CSBM, and in symp toms will be analyzed wi th similar ANCOVA models. 
 
Time to occurrence of SBM after intake of  the first Vibrant capsule (either active or  placebo) will be asse ssed and presented b y 
Kaplan-Meier curves and will be compared between the study arms using the Log-Rank test if relevant. 
 
Treatment satisfaction, and incidence of use of rescue medication will  be presented in tabular form. 
The PAC-QoL, the rescue medication use, and the rate of SBM during the first [ADDRESS_1165129] dose will be presented in  tabular 
form. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 73 of 99 
 
 
 
17.9.6  Treatment by [CONTACT_838679] a significance level of 10%. 
Poolability across centers, for the primary endpoints, w ill be assessed using a logistic regression model.  
Centers will be grouped together by [CONTACT_838680], a table of the s ites and their geographical ar ea within and without the [LOCATION_003] will 
be presented. If found significant,  the reason for the sign ificance would be further explored  and rationalized. This evaluation  may 
include demographic features, symptoms at presentation, clinical and trea tment history, and site comp arability in the features found to 
be associated with the primary performance variable. 
Pooling analysis will be repeated  with US centers combined, and Ou t of US (OUS) centers combined. 
 
17.9.7  Safety Analysis 
Adverse events (AE) will be presented by [CONTACT_12917], severity and relation to tr eatment by [CONTACT_1570]. The number of repo rts, 
the number of subjects, and the incidence (percent of subjects)  will be tabulated by [CONTACT_30157]. 
17.9.8  Handling of Missing Data 
 
Subjects with less than 6 weeks of diary data will be c onsidered as failures for the CSBM and SBM success rates. 
Multiple imputation for binary da ta will be used as the primar y imputation method in the case of missing data for the primary 
performance end-point, baseline  variable to be used in the analysis: BMI, se x, Age, duration of historical symptoms, straining and 
Bristol stool scale at baseline. Once the data  is finalized if this method is deemed inappropriate a more appropriate analysis may be 
performed.  
Additional sensitivity analysis of the primary end-point will be  performed to assess the impac t of missing data on the study ou tcome 
using possible imputation me thods for binary data:  
• Tippi[INVESTIGATOR_18275]. 
• Observed Data: Use only subjects with 8 weeks of non-mi ssing diary data and who did not  withdraw early from study. 
• Best Case Scenario: Assume all subjects with missing data in study group are successes; Assume all subjects in the 
placebo group with missi ng data are failures. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 74 of 99 
 
 
 
• Worst Case Scenario: Assume all subjects with missing data  in study group are failures; Assume all subjects in the 
placebo group with missi ng data are successes. 
 
In addition, for missing diary day, th e number of bowel movement will be  imputed to “0”, and the inta ke of rescue medicine to “ No”. 
For the time to first SBM analys is, subjects with no known SBM will be considered left censored. 
For the analyses of the other endpoints, no imp utations for missing valu es will be performed. 
18. DATA	MONITORING 	PLAN		
The Principal Investigator [INVESTIGATOR_688975]. In addition a da ta monitor will visit the study s ite during 
the study and review the progress of  the clinical trial including sa fety data and ensure as possi ble that it is conducted, reco rded, and 
reported in accordance with the protocol, Good Clinical Practice (GCP), and the app licable regulatory requ irement(s). A written  report 
form will be issued after each monitoring visit (including initiation and close out vi sits). The monitoring visit report will i nclude a 
summary of what the monitor reviewed a nd the monitor's statements concerning the significant findings/fac ts, deviations and 
deficiencies, conclusions, actions taken or to be taken and/or actions recommended to secure compliance. The investigator/insti tution 
should provide direct access to source data/documents for tria l-related monitoring and auditing, IRB/IEC review and inspection by [CONTACT_838681] y authority/ies.  
 
NOTE: e-Source may be used. 
 
Verification during monito ring visit will include: 
 
1. That the investigator has adequate qualif ications and resources and remains adequate  throughout the trial period, that facility , 
including laboratories, equi pment, and staff, are ad equate to safely and properly conduct the trial and remain adequate through out 
the trial period. 
2. Verifying for the inves tigational product(s): 
a. That storage conditions are acceptable. 
b. That the investigational product(s) are s upplied only to subjects who are eligible to  receive it according to protocol and 
no other use is being done with the Vibrant devices. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165130](s)  at site are controlled a nd documented adequately and 
that supplies delivery notes are conf irmed upon reception th roughout the trial. 
d. That the unused investigational product(s) at sites will be returned. 
3. Verifying that the investigator fo llows the approved protocol and all approved amendment(s), if any. 
4. Verifying that written informed c onsent was obtained before each subject 's participation in the trial. 
5. Ensuring that the investigator r eceives the current Investigator's Brochure, a ll documents, and all trial supplies needed to co nduct 
the trial properly and to comply with th e applicable regulato ry requirement(s). 
6. Ensuring that the investigator and th e investigator's trial staff are adeq uately informed about the trial. 
7. Verifying that the investigator and the investigator's trial staff are performing the specifie d trial functions, in accordance with the 
protocol and any other written agreem ents, and have not delegated these f unctions to unauthorized individuals. 
8. Verifying that the investigator is enrolling only eligible subjects and at sufficient recruitment rate. 
9. Verifying that source documents and ot her trial records are accurate, complete, kept up-to-date and maintained. 
10. Verifying that the investigator provides all the required reports, notifications , applications, and sub missions, and that these  
documents are accurate, complete, timely, le gible, dated, and identify the trial. 
11. Checking the accuracy and completeness of th e CRF entries, source documents and other trial-related records against each other.   
12. The data required by [CONTACT_838682] c onsistent with the source documents. 
13. Adverse events, concomitant medications and intercurrent illnesse s are reported in accordance with the protocol on the CRFs. 
14. Visits that the subjects fail to  make, tests that are not conduc ted, and examinations that are not performed are clearly report ed as 
such on the CRFs. 
15. All withdrawals and dropouts of en rolled subjects from the trial are reported and explained on the CRFs. 
16. Verifying that the investigator had answered all of the queries that came up from inspection of the CRFs or other trial materia l. 
17. That the investigator is maintaining the essential documents.  
18. Verifying that deviations fro m the protocol, SOPs, GCP, a nd the applicable re gulatory requirement s are reported by [CONTACT_421905]/IEC and that a ppropriate actions were taken to prevent recurrence of the detected deviations. 
 
Should there be an unexpected number of de vice failures or related compli cations that increase the ri sks to the participants, o r critical 
efficacy endpoints at intervals that are not  satisfying, the study will be halted and an alysis performed to determine whether t o 
continue, modify the prot ocol, or close the study. 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165131] will be identified by [CONTACT_5657]/ her initials and a unique subject identification number. Source data will be stored wit h source 
documents. The Investigator Site Files (ISF)  will be held in a secure area. The s ubject’s name [CONTACT_207565]. However, the s ponsor’s monitor or representative and regulatory representati ves, 
auditors and inspectors may have access to medical files in order to verify authenti city of data collected. 
 
20. FUNDING 		
 
The study is funded by [CONTACT_465097].  
21. ETHICS		
 
Prior to study initiation the site  shall obtain EC or IRB approva l of the study. A copy of the wr itten EC approval must be prov ided to 
the sponsor prior to the start of the study. 
Any changes in the study protocol, informed consent forms, or investigator must be re-approved by [CONTACT_838683] l 
documented. All subjects screened in the study will provide thei r consent prior to entering the study. An informed consent form  shall 
be signed and dated by [CONTACT_423]. Th e investigator will reta in the forms as part of the study records.  
This study will be executed in accordance wi th the Declaration of Helsinki, in agre ement with the guidelines for conducting a c linical 
investigation in accordance with the principl es of ICH GCP outlined in the E6 document. By [CONTACT_207552], the 
investigator commits to carry it out in accordance with local legal requirements. 
 
Other investigator responsi bilities relative to the EC/IRB include the following: 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165132] of the study, the investigat or will submit progress reports to the EC /IRB as required, and request re-review and 
approval of the study at least once a year; 
2. The investigator will report immediately to the EC /IRB of any unexpected serious adverse ev ents that occur during the study, and 
provide the sponsor with a copy of the correspondence; 
3. If the sponsor notifies about serious adverse events reported in other st udies using this device, th e investigator must report that 
information to the EC /IRB; 
4. As required, the investigator mu st obtain approval from the EC fo r protocol amendments and for re visions to the consent form or  
subject recruitment advertisements; 
5. The investigator should provide the EC /IRB with any other informa tion it requests before or  during conduct the study; 
6. The investigator must maintain a fi le of study-related inform ation that includes all correspondence with the EC /IRB; 
7. The investigator must notify EC /IRB when study is completed (i.e. after the la st study visit of the final study subject); 
8. After study completion (within 12 months is reco mmended) the investigator should provide the EC /IRB with a final report on the 
study. The recommended components of a fina l report are as follows; dates of study st art and completion, number of subjects 
enrolled/treated, number of subjects w ho discontinued participation early and r eason why, itemization a nd discussion of any 
serious adverse event. 
  
22. INFORMED 	CONSENT 		
 
Written informed consent must be obtained from each study subject. The subject will be asked to r ead the informed consent form and 
to sign the form to indicate cons ent to participate in the study.  
The investigator will explain carefully to the subject the research nature of the st udy. The scope and aims of the research wil l be 
described together with known or foreseeabl e benefits, risks and discomforts that su bjects may experience. Appropriate alternat ive 
treatments will be discussed so that the subj ect may determine whether or not he or she wishes to participate in the study.  Th e subject 
must understand that throughout th e study his or her participati on remains voluntary and protected by [CONTACT_838684].  
The investigator is responsible for obtaining written (or witnessed) informed c onsent from potential s ubjects prior to study en try.  
Subjects will be given time to read the in formed consent and ask any questions before  being asked to sign the form.  The inform ed 
consent (approved by [CONTACT_838685]) must be signed and dated by [CONTACT_24484]. One co py 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165133]'s consent form ma y be revised to reflect the cha nges of the protocol. It is th e 
responsibility of the investigator to ensure that an amended info rmed consent is approved or re viewed by [CONTACT_1383]/IRB, and that i t is 
signed by [CONTACT_838686] d in the study and those currently in th e study, if affected  by [CONTACT_29991]. 
 
23. REGULATORY 	AND	HEALTH	AUTHORITY 	AUDITS	
The European Union’s authorities and/or the Food and Drug Administration (FDA) and/or  the local state hea lth authorities may 
request access to all study record s, including source documents for inspection. Th e investigator and hospi[INVESTIGATOR_838661]. The investigator must notify the spons or of any health authority a udit as soon as notification of such audit 
is made. A representative or de signee of the sponsor may also conduct similar au dits and may be present during health authority  audit. 
 
24. ELECTRONIC 	REPORTING 	OF	DATA	
 
All medical data in this trial are to be recorded directly in the ED C (Electronic Data Capture) system. Documentation on paper will be 
restricted to exceptional circumstances only. 
The investigator must ensure the accuracy, co mpleteness and timeliness (and legibility in 
case of documentation on paper) of data. 
 
Sites will get trained on how to access and use the EDC and w ill be foreseen with a personal user login and password.  
Subjects will access and complete their diar ies online via a website specifically crea ted for the purposes of the study. Subjec ts will be 
trained on how to access and use this website and will be  foreseen with a personal user login and password. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165134] 	RETENTION 	
It is required that a copy of  all records (e.g., informed cons ent documents, source documents, safety reports, study device dis pensing 
record, etc.) which support case re port forms for this study, be re tained in the files of the re sponsible investigator for a mi nimum of 
fifteen (15) years following notific ation by [CONTACT_838687] i nvestigations (not merely the investigator's portion) are co mpleted, 
terminated and/or discontinued.  If the principal investigator [INVESTIGATOR_1496], relocate s, or for other reasons  withdraws from the resp onsibility 
of keepi[INVESTIGATOR_8090], custody must be transferred to a person wh o will accept the responsib ility. Vibrant Ltd. must be notified 
in writing of the name [CONTACT_1640]. 
26. PROTOCOL 	MODIFICATIONS 	
An amendment to the protocol may be propos ed by [CONTACT_689001]. The amendment will be prepared and approved by 
[CONTACT_207557]’s relevant SOP. The amendm ent must be submitted to the EC/IRB. When applicable, the 
amendment’s implementation will take place only once approved by [CONTACT_1383]/IRB. 
If for any unexpected reasons, there is any requirement to deviate from th e treatments stated above, the protocol deviation sho uld be 
discussed in advance with a Vibrant Ltd. representative.  
 
27. PUBLICATION 	POLICY	
All information concerning this study that was not previously published is considered  confidential informa tion. This confidenti al 
information shall remain the sole property of Vibrant Ltd.; it shall not be disclosed to others  without written consent of Vibr ant Ltd. 
and shall not be used except in  the performance of this study. 
Any investigator involved with th is study is obligated to provide the Sponsor with  complete test results and all data derived f rom the 
study. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165135] 	/	STUDY	DISCONTINUATION 	
 
Subjects should be removed from the study when ever considered necessary for their welfar e or when the subject expresses a desir e to 
withdraw from the study. Non-co mpliance with the protocol, the occurrence of a Serious Adverse Event or any medical condition t hat, 
in the opi[INVESTIGATOR_2511] i nvestigator, warrants discontinuati on from the study for the safety of the subject, may necessitate disc ontinuing a 
subject. If a subject is discontinued, the reason must be entered on th e case report form and signed  by [CONTACT_093]. In ca se of any 
questionable situation, the study monitor or Vibrant Ltd. personnel should be consulted. When a subj ect is removed from the stu dy as 
a result of Serious Adverse Event, a fina l physical examination must be performed. Subjects removed from th e study because of a n 
adverse event will be followed-up until the adverse event has been resolved. 
 
In the case that the occurrence of adverse events is greater th an anticipated, the clinical inve stigation will be suspended; in  such a case, 
a safety committee will be arranged to decide if the study coul d be continued. The Ethics Com mittee will be notified and the re sults of 
the safety committee discussions will be brought for the EC/IRB re view and decision. 
 
Early termination could be a result of: 
1. Withdrawal of informed consent by [CONTACT_423]. 
2. Subjects who after inclusion develop medica l diseases which may affect the functi on and interpretation of study results. 
3. Serious protocol deviation. 
4. Non-compliance with medical device administration or study procedures  as determined by [CONTACT_456]. 
5. Change in subject's condition. 
6. Subject is Lost to follow-up. 
7. Confirmed pregnancy. 
8. Regulatory authorities stop the trial. 
 
During the study, subjects exiting the trial will be replaced with new subjects, up to 10%  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165136] medic al records, 
CRF and in center log. 
 
Each clinical investigator will be respons ible for the safe storage with restricted  access of the investigational materials in their possession, 
thereby [CONTACT_838688] a ny persons not participating in the study. 
All base units and remaining capsules (untouched or taken out of the blister package) must be brought back by [CONTACT_838689] t he site 
by [CONTACT_838690]. The number of remaining capsules must matc h the information transmitted by [CONTACT_838691]’s tr eatment compliance th roughout the study. In or der to perform thi s task, 
the Sponsor, CRO and study coordinato r will rely on the same platfo rm used to monitor protocol deviations related to treatment 
compliance.  A final account, and the whereabouts of each capsule provided to the subject will be documented in the EDC by [CONTACT_20234]. Capsule failures will not be  documented in the EDC but on the external platform, using the ba se unit information. 
 
After completion of the study, all un used or remaining devices must be returned in  their original package to Vibrant Ltd. Hakoc hav, 
Yokneam [ADDRESS_1165137] inventor y and 
records. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 82 of 99 
 
 
 
30. APPENDICES 	
Appendix A – Bristol Stool Scale 
Appendix B - Rome III questionnaire and instructions for completion 
Appendix C – Ease of use questionnaire Appendix D – Patient Assessment of Constipatio n Quality of Life (PAC-QOL) Questionnaire 
Appendix E – TSQM questionnaire 
 
 
 
 
31. REFERENCES 		
 
1. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of 
chronic constipation in Nort h America. Am J Gastroente rol. 2005;[ADDRESS_1165138] 1:S1–4. 
2. Wilson N, Schey R. Lubiprostone in co nstipation: clinical eviden ce and place in therapy. Th er Adv Chronic Dis. 2015 
Mar;6(2):40–50. 
3. Johanson JF, Kralstein J. Chronic constipation: a survey of  the subject perspective. Aliment Pharmacol Ther. 2007 Mar 
1;25(5):599–608. 
4. Rome III Diagnostic Criteria [Internet] . [Accessed 2015 Nov 3]. Available from: http://www.romecriteria.org/criteria/  
5. Only 27% of European subjects with chroni c constipation are satisfied with current tr eatment options [Internet]. [Accessed 2015  
Nov 3]. Available from: https://www.ueg.eu/education/document-
detail/?name=only_27_of_european_subjects _with_chronic_constipation_ are_satisfied_with_current _treatment_options&file=
[ZIP_CODE]  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165139] AC, Moayyedi P, Lacy BE, Lembo AJ , Saito YA, Schiller LR, et  al. American College of Gastroenterolo gy monograph on 
the management of irritable bowel syndrom e and chronic idiopathic co nstipation. Am J Gastroen terol. 2014 Aug;[ADDRESS_1165140] 
1:S2–26; quiz S27. 
7. Paré P, Fedorak RN. Systematic review of  stimulant and nonstimulant laxatives for th e treatment of functi onal constipation. Can  
J Gastroenterol Hepato l. 2014 Nov;28(10):549–57. 
8. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB,  MacDougall JE, Jia XD, et al. Two rando mized trials of lin aclotide for chronic 
constipation. N Engl J Med. 2011 Aug 11;365(6):527–36. 
9. Soubra M, Schey R. Lubiprostone for the treatment of adult women w ith irritable bowel syndrome with constipation. Clin Med 
Insights Gastroente rol. 2012;5:23–30.  
10. Wald A. Severe constipation. Clin Ga stroenterol Hepatol 2005; 3: 432–5. 
11. Cheung O, Wald A. Management of pelvic floor disorders. Aliment Pharmacol Ther 2004; 19: 481–95. 
12. Tack J, Müller-Lissner S, Stanghellini V, Boeckxstaens G, Kamm MA, Simren M, et  al. Diagnosis and tr eatment of chronic 
constipation--a European perspective. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2011 Aug;23(8):697–710.  
13. Do Stool Form and Frequency Correlate With Whole-Gut and Colonic Transit ?  Results From a Multicenter Study in 
Constipated Individuals and Healt hy Controls [Accessed March 30th, 2016 
https://www.researchgate.net/pub lication/38066000_Do_Stool_Form_and_F requency_Correlate_With_Whole-
Gut_and_Colonic_Transit_Results_From_a_Multicenter_St udy_in_Constipated_Individua ls_and_Healthy_Controls] 
14. T2081 Bristol Stool Form in Slow Transit Constipation Correlates Inversely With Re gional Colon Contractile  Activity Measured 
by a Wireless Motility Capsule [A ccessed March 30th, 2016 http://www.gast rojournal.org/arti cle/S0016-5085%2810%2962894-
6/pdf] 
15. Stool form scale as a useful guide to intes tinal transit time. [A ccessed March 30th, 2016 
http://www.ncbi.nlm.nih.gov/pubmed/9299672] 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 84 of 99 
 
 
 
16. Atkinson MJ, Sinha A, Hass SL, et al. Valid ation of a general measure of treatment satis faction, the Treatment Satisfaction 
Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. 
Those seeking information regarding or permission to use the TSQM are directed to Quintil es at www.quintilesims.com/TSQM 
or [EMAIL_4063]  
17. http://www.earthmicr obiomeproject.org/  in 
18. Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushma n, F. D., Costello, E. K., Fierer, N., Pena, A. G., Goodric h, 
J. K., Gordon, J. I., Huttley, G. A., Kelley,  S. T., Knights, D., Koenig, J. E., Ley, R. E., Lozupone, C. A., McDonald, D., Mue gge, 
B. D., Pi[INVESTIGATOR_688977], M., Reeder, J., Sevinsky, J. R., Turnbaugh, P. J ., Walters, W. A., Widmann, J., Yatsunenko, T., Zaneveld, J. & 
Knight, R. (2010) QIIME allows analysis of high-throughput commun ity sequencing data, Nat Methods. 7, 335-6. 
19. Caporaso JG, L. C., Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betle y J, Fraser L, Bauer M, Gormley N, 
Gilbert JA, Smith G, Knight R (2012) Ultra-high throughput mic robial community analysis on the Illumina HiSeq and MiSeq 
platforms, Isme J. 6, 1621-1624. 
20. Goodrich, J. K., Di Rienzi, S. C., Poole, A. C., Koren, O., Wal ters, W. A., Caporaso, J. G., Kn ight, R. & Ley, R. E. (2014) 
Conducting a microbiome study, Cell. 158, 250-62. 
21. Werner, J. J., Koren, O., Hugenholtz, P., DeSantis, T. Z., Walters , W. A., Caporaso, J. G., Angenent, L. T., Knight, R. & Ley, 
R. E. (2012) Impact of training se ts on classification of high-throughput  bacterial 16s rRNA gene surveys, Isme J. 6, 94-103. 
22. Koren, O., Knights, D., Gonzalez, A., Waldr on, L., Segata, N., Knight, R., Huttenhow er, C. & Ley, R. E. (2013) A guide to 
enterotypes across the human body: meta-a nalysis of microbial comm unity structures in hum an microbiome datasets, PLoS 
computational biology. 9, e1002863. 
23. Koren, O., Goodrich, J. K., Cullender, T. C., Spor, A., Laitinen, K., Backhed, H. K., Gonzalez, A ., Werner, J. J., Angenent, L.  
T., Knight, R., Backhed, F., Isolauri, E., Salminen, S. & Ley, R.  E. (2012) Host remodeling of the gut microbiome and metabolic  
changes during pregnancy, Cell. 150, 470-80. 
24. Koren, O., Spor, A., Felin, J., Fak, F., Stom baugh, J., Tremaroli, V., Behre, C. J., Knight, R., Fagerberg, B., Ley, R. E. & 
Backhed, F. (2011) Human oral, gut, and plaque microbiota in patients with atherosclerosis, Proc Natl Acad Sci U S A. [ADDRESS_1165141] 1 , 4592-8 
25. Winge, K., Rasmussen, D. & Werdelin, L. Cons tipation in neurological diseases. J.      Neurol. Neurosur g. Psychiatry 74, 13–
19 (2003). 
26. Müller HH, Schäfer H., Adaptive group sequentia l designs for clinical  trials: combining     the advantages of adaptive and of 
classical group sequential approa ches. Biometrics. 2001;57:886-891.  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165142]. Med. 2001; 20:2645–2660 
28. Broberg, Sample size re-assessment  leading to a raised sample size does not inflate type I er ror rate under mild conditions. 
Medical Research Methodology 2013, 13:94 
 
 
      
 
      
 
 
   
 
   
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 86 of 99 
 
 
 
APPENDIX A – Bristol Stool Scale 
 
 
The Bristol Stool Scale:  
 How to analyze stools: 
 Type 1:  Stools appear in separate, hard  lumps, similar to nuts. Type 
[ADDRESS_1165143] amount of time; a sure sign 
you’re constipated; most common stools. 
 Type 2:  Stools are sausage-like in ap pearance but lumpy. Indicate 
toxic constipation and need for intestinal cleansing 
 Type 3 (Normal):  Stools come out similar to a sausage but with 
cracks in the surface. 
 Type 4 (Normal):  Stools are smooth and so ft in the form of a 
sausage or snake. 
 Type 5:  Stools form soft blobs with cl ear-cut edges, and easily pass 
through the digestive system. Soft  diarrhea, it may indicate a 
possible risk for bowel disease; al so indicate you are toxic and need 
regular intestinal cleansing. 
 Type 6:  Stools have fluffy pi[INVESTIGATOR_6927]. Considered 
mushy stools, they indicate dia rrhea; and that you are toxic and 
need regular intestinal cleansing. 
 Type 7:  Stool is mostly liquid with no solid pi[INVESTIGATOR_6928]. Passed quickly 
through the colon; is indicative of  severe diarrhea  possibly as a 
result of a viral or bacterial infection. See a doctor as soon as 
possible. 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 87 of 99 
 
 
 
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 88 of 99 
 
 
 
APPENDIX B – ROME III (Questionnair e and Instructions for Completion) 
 
Instructions for completion: 
Complete questions 41 to 67 only.  
Scoring Algorithm:  
 
Irritable Bowel Syndrome 
Diagnostic Criteria* 
Recurrent abdominal pain or discomfort at leas t 3 days/month in last 3 months associated with two or more of criteria #1– #3  below: 
Pain or discomfort at least 2–3 days/month  (question 41 > 2) 
For women, does pain occur only during menstrual bleeding?  (question 43=0 or 2) 
1. Improvement with defecation 
Pain or discomfort gets better after BM at least sometimes  (question 46 > 0) 
2. Onset associated with a cha nge in frequency of stool 
Onset of pain or discomfort associated with more stools at least sometimes (question 47 > 0), OR 
Onset of pain or discomfort associated with fewer stools at least sometimes (question 48 > 0) 
3. Onset associated with a change in form (appearance) of stool 
Onset of pain or discomfort associated with looser stools at least sometimes (question 49 > 0), OR 
Onset of pain or discomfort associated with harder stools at least sometimes  (question 50 > 0) 
* Criteria fulfilled for the last [ADDRESS_1165144] 6 months prior to diagnosis 
Yes. (question 45=1)  
    
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 89 of 99 
 
 
 
Functional Constipation 
Diagnostic criteria* 
1. Must include two or mo re of the following: 
a. Straining during at least 25% of defecations. At least often.  (question 54 > 1) 
b. Lumpy or hard stools at least 25% of defecations. At least often.  (question 53 > 1) 
c. Sensation of incomplete evacuation at least 25% of defecations. At least sometimes.  (question 55 > 0) 
d. Sensation of anorectal obstruction/bloc kage at least 25% of defecations. At least sometimes.  (question 56 > 0) 
e. Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor). At least sometimes.  
(question 57 > 0) 
f. Fewer than three defecations per week. At least often . (question 52 > 1) 
 
2. Loose stools are rarely present without the use of laxatives. 
Loose stools occur never or rarely  (question 49=0), & 
3. Insufficient criteria for IBS 
Diagnostic criteria for IBS not met 
* Criteria fulfilled for the last [ADDRESS_1165145] 6 mont hs prior to diagnosis. Yes. (question 59=1) 
 
 
    
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 90 of 99 
 
 
 
 
APPENDIX C – Ease of use questionnaire 
 
Please	rank	the	following 	tasks	and	propositions 	on	a	scale	from	1	to	5	
(Circle the response that be st represents your opi[INVESTIGATOR_1649])  
[1] Connecting the base unit to Wi-Fi 
[ADDRESS_1165146] Medium Easy Very Easy  
[2] Setting up the base unit for use 
[ADDRESS_1165147] Medium Easy Very Easy  
[3] Activating capsules 
[ADDRESS_1165148] Medium Easy Very Easy  
[4] Knowing if the capsules have been successfully activated or not 
[ADDRESS_1165149] Medium Easy Very Easy  
[5] Following the treatment for several mo nths once it is commercialized (there 
would be no need to connect the base unit to Wi-Fi)  
[ADDRESS_1165150] Medium Easy Very Easy  
[6] How likely would you be to use the capsule if it is commercially available in the 
future?  
1	 2	 3	 4	 5		
Not at all likely Not likely Neutral Likely Very likely  
 
 
  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 91 of 99 
 
 
 
 
  
 
  
 
APPENDIX D – Patient Assessment of Constipati on Quality of Life (PAC-QOL) Questionnaire  
 
The following questions are designed to measure th e impact constipation has had on your daily life over the past [ADDRESS_1165151] you . . . Not at all 
1 A little bit 
2 Moderately 
3 Quite a bit 
4 Extremely 
5 
1. Felt bloated to the point of bursting? ☐ ☐ ☐ ☐ ☐ 
2. Felt heavy because of your constipation? ☐ ☐ ☐ ☐ ☐ 
The next few questions ask about how constipa tion affects your daily life. During the 
past [ADDRESS_1165152] of the 
time 
4 All of the 
time 
5 
3. Felt any physical discomfort? ☐ ☐ ☐ ☐ ☐ 
4. Felt the need to have a bowel movement but not been able to? ☐ ☐ ☐ ☐ ☐ 
5. Been embarrassed to be with other people? ☐ ☐ ☐ ☐ ☐ 
6. Been eating less and less because of not being able to have bowel movements? ☐ ☐ ☐ ☐ ☐ 
The next few questions ask about how constipa tion affects your daily life. During the 
past [ADDRESS_1165153] you . . . Not at all 
1 A little bit 
2 Moderately 
3 Quite a bit 
4 Extremely 
5 
7. Had to be careful about what you eat?  ☐ ☐ ☐ ☐ ☐ 
8. Had a decreased appetite?  ☐ ☐ ☐ ☐ ☐ 
9. Been worried about not being able to ch oose what you eat (for example, at a 
friend’s house)? ☐ ☐ ☐ ☐ ☐ 
10. Been embarrassed about staying in the bathroom for so long when you were 
away from home? ☐ ☐ ☐ ☐ ☐ 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: [ADDRESS_1165154] from home? ☐ ☐ ☐ ☐ ☐ 
12. Been worried about having to change your daily routine (for example, 
traveling, being away from home)? ☐ ☐ ☐ ☐ ☐ 
 
 
 
The next few questions ask about your feeli ngs related to constipation. During the past 
[ADDRESS_1165155] of the 
time 
4 All of the 
time 
5 
13. Felt irritable because of your condition?  ☐ ☐ ☐ ☐ ☐ 
14. Been upset by [CONTACT_86965]?  ☐ ☐ ☐ ☐ ☐ 
15. Felt obsessed by [CONTACT_86965]?  ☐ ☐ ☐ ☐ ☐ 
16. Felt stressed by [CONTACT_86965]?  ☐ ☐ ☐ ☐ ☐ 
17. Felt less self-confident because of your condition?  ☐ ☐ ☐ ☐ ☐ 
18. Felt in control of your situation?  ☐ ☐ ☐ ☐ ☐ 
The next questions ask about your feelings related to constipation. During the past [ADDRESS_1165156] a 
bowel movement? ☐ ☐ ☐ ☐ ☐ 
20. Been worried about not being able to have a bowel movement? ☐ ☐ ☐ ☐ ☐ 
21. Been increasingly bothered by [CONTACT_207561] a bowel movement? ☐ ☐ ☐ ☐ ☐ 
The next questions ask about your life with constipation. During the past [ADDRESS_1165157] of the 
time 
4 All of the 
time 
5 
22. Been worried that your co ndition will get worse?  ☐ ☐ ☐ ☐ ☐ 
23. Felt that your body was not working properly?  ☐ ☐ ☐ ☐ ☐ 
24. Had fewer bowel movements than you would like? ☐ ☐ ☐ ☐ ☐ 
The next questions ask about your degree of  satisfaction related to constipation. 
During the past [ADDRESS_1165158] a bowel movement?  ☐ ☐ ☐ ☐ ☐ 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 93 of 99 
 
 
 
26. Satisfied with the regularity of your bowel movements?  ☐ ☐ ☐ ☐ ☐ 
27. Satisfied with the time it takes for food to pass through the intestines? ☐ ☐ ☐ ☐ ☐ 
28. Satisfied with your treatment? ☐ ☐ ☐ ☐ ☐ 
 
 
 
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 94 of 99 
 
 
 
APPENDIX E– TSQM Questionnaire 
 
TSQM  (Version 1.4)  
Treatment Satisfaction Questionnaire for Medication 
 
Instructions:  Please take some time to th ink about your level of satisfaction or 
dissatisfaction with the treat ment you are taking in this  clinical trial.  We are 
interested in your evaluati on of the effectiveness, side effects, and convenience of 
the treatment over the last two to three w eeks, or since you last used it .  For each 
question, please place a single check mark next  to the response that most closely 
corresponds to your own experiences.  
 
1. How satisfied or dissatisfied are you with the ability of the treatment to prevent or treat your 
condition?  
 
□1   Extremely Dissatisfied 
□2   Very Dissatisfied 
□3   Dissatisfied 
□4   Somewhat Satisfied 
□5   Satisfied 
□6   Very Satisfied 
□[ADDRESS_1165159] the treatment relieves your symptoms?  
 
□1   Extremely Dissatisfied 
□2   Very Dissatisfied 
□3   Dissatisfied 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 95 of 99 
 
 
 
□4   Somewhat Satisfied 
□5   Satisfied 
□6   Very Satisfied 
□7   Extremely Satisfied 
 
3. How satisfied or dissatisfied are you with the amount of time it takes the treatment to start 
working?  
 
□1   Extremely Dissatisfied 
□2   Very Dissatisfied 
□3   Dissatisfied 
□4   Somewhat Satisfied 
□5   Satisfied 
□6   Very Satisfied 
□7   Extremely Satisfied  
 
 
4.  As a result of taking this treatment, do you experience any side effects at all? 
 
□1   Yes 
□0   No  (if No, then please skip to Question 9) 
 
 
5. How bothersome are the side effects of the treatment you take to tr eat your condition?  
 
□1   Extremely Bothersome 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 96 of 99 
 
 
 
□2   Very Bothersome 
□3   Somewhat Bothersome 
□4   A Little Bothersome  
□5   Not at All Bothersome 
 
6. To what extent do the side e ffects interfere with your physica l health and ability to function 
(i.e., strength, energy levels, etc.)?  
 
□1   A Great Deal 
□2   Quite a Bit 
□3   Somewhat 
□4   Minimally 
□5   Not at All 
 
7. To what extent do the side e ffects interfere with your mental function (i.e., ability to think 
clearly, stay awake, etc.)?  
 
□1   A Great Deal 
□2   Quite a Bit 
□3   Somewhat 
□4   Minimally 
□[ADDRESS_1165160] treatment side effects affected your overall satisfaction with the 
treatment?  
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 97 of 99 
 
 
 
 
□1   A Great Deal 
□2   Quite a Bit 
□3   Somewhat 
□4   Minimally 
□5   Not at All 
 
9. How easy or difficult is it to us e the treatment in its current form?  
 
□1   Extremely Difficult 
□2   Very Difficult 
□3   Difficult 
□4   Somewhat Easy 
□5   Easy 
□6   Very Easy 
□7   Extremely Easy 
 
10. How easy or difficult is it to plan when you will use the treatment each time?  
 
□1   Extremely Difficult 
□2   Very Difficult 
□3   Difficult 
□4   Somewhat Easy 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 98 of 99 
 
 
 
□5   Easy 
□6   Very Easy 
□7   Extremely Easy 
 
11. How convenient or inconvenient is it  to take the treatment as instructed?  
 
□1   Extremely Inconvenient 
□2   Very Inconvenient 
□3   Inconvenient 
□4   Somewhat Convenient 
□5   Convenient 
□6   Very Convenient  
□7   Extremely Convenient 
 
 
12. Overall, how confident are you that taking this treatment is a good thing for you?   
□1   Not at All Confident 
□2   A Little Confident 
□3   Somewhat Confident 
□4   Very Confident  
□5   Extremely Confident 
 
13. How certain are you that the good things ab out your treatment outweigh the bad things?  
 
 VIBRATING CAPSULE 
PROTOCOL FOR STUDY V-270 Doc No: 270CLD  
Rev: 01 Date: 24 Jan 2019 
Page 99 of 99 
 
 
 
□1   Not at All Certain 
□2   A Little Certain  
□3   Somewhat Certain 
□4   Very Certain 
□5   Extremely Certain 
 
14. Taking all things into account, how satisfied or dissatisfied are you with this treatment?  
 
□1   Extremely Dissatisfied 
□2   Very Dissatisfied 
□3   Dissatisfied 
□4   Somewhat Satisfied 
□5   Satisfied 
□6   Very Satisfied  
□7   Extremely Satisfied 
 
  Copyright Quintiles 2017. All rights reserved. 
 
  